

*PBS  
Expenditure  
and  
Prescriptions  
Report  
1 July 2020  
to  
30 June 2021*



Australian Government  
Department of Health

***PBS Information Management Section  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division***

This publication and previous editions can be accessed via the internet:  
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director  
PBS Information Management Section  
Pricing and PBS Policy Branch, MDP 900  
Department of Health  
GPO Box 9848 Canberra ACT 2601

E-mail: [pbsstats@health.gov.au](mailto:pbsstats@health.gov.au)

## Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by approved suppliers. Claims of manually processed PBS programs are excluded.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The financial information in this publication is presented on a cash (expenditure) basis, except where indicated otherwise.

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2021, the general patient safety net threshold was **\$1,497.20**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.60** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$316.80**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by Services Australia. The historical data from 1948-49 to 2015-16 on pages 28 to 33 remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) on pages 28 to 29 and Table 21(b) on pages 30 to 33, because of a past problem in data supplied by the Services Australia whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed for 2008-

09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Remote Area Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 1.

Expenditure on nusinersen was adjusted to include manual payments that were not processed through the PBS Online system.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

## Summary of the Pharmaceutical Benefits Scheme 2020-2021

Total Pharmaceutical Benefits Scheme (PBS) Government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2020-21 financial year was **\$13.8 billion** (excluding revenue), compared with **\$12.6 billion** for the previous year. This is an increase of **9.0%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Total 2020-21 PBS subsidised prescription volume increased by **2.4%** to a total of **213.6 million**, compared to **208.5 million** for the 2019-20 financial year.

In 2020-21, PBS Government expenditure on a cash accounting basis for the supply of medicines under Section 85 and Section 100 was **\$13.6 billion** (excluding rebates) which is **90.0%** of the total cost of PBS prescriptions. The remainder was patient contributions, which amounted to **\$1.5 billion**.

The majority of Government expenditure in 2020-21 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$9 billion, 66.3% of the total**), compared to concessional cardholders expenditure for 2019-20 (**\$8.3 billion, 66.0% of the total**).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines increased to **\$70.65** in 2020-21, compared to **\$67.34** in 2019-20.

There were **906** different medicines in **5,380** brands listed on the PBS as at 30 June 2021.

## List of tables

Table	Description	Page
Table 1(a)	PBS Expense on an Accrual Accounting Basis, 2019-20 and 2020-21	1
Table 1(b)	PBS Section 100 Programs on an Accrual Accounting Basis, 2019-20 and 2020-21	1
Table 2(a)	PBS Prescriptions, 2019-20 and 2020-21 (incl. under co-pay prescriptions)	2
Table 2(b)	PBS Government Cost, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	2
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	2
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	2
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21 (excl. under co-pay prescriptions)	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21 (excl. under co-pay prescriptions)	3
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2020-21 (excl. under co-pay prescriptions)	4
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21 (excl. under co-pay prescriptions)	5
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2020-21 (excl. under co-pay prescriptions)	6
Table 5(c)	Top 25 PBS Cancer Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21 (excl. under co-pay prescriptions)	7
Table 5(d)	Top 25 PBS Biologic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21 (excl. under co-pay prescriptions)	7
Table 6	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2020-21 (incl. under co-pay prescriptions)	8
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2020-21 (incl. under co-pay prescriptions)	9
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	10
Table 9(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2019-20 and 2020-21 (excl. under co-pay prescriptions)	11
Table 9(b)	Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2019-20 and 2020-21 (excl. under co-pay prescription)	12
Table 10(a)	PBS Section 85 Prescription Volume, 2017-18 to 2020-21 (incl. under co-pay prescriptions, Section 85 only)	13

Table 10(b)	PBS Section 85 expenditure, 2017-18 to 2020-21 (excl. under co-pay prescriptions, Section 85 only)	13
Table 11	PBS Prescriptions and Government Cost by Formulary, 2020-21 (incl. under co-pay prescriptions)	14
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2020-21 (incl. under co-pay prescriptions)	15
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2020-21 (incl. under co-pay prescriptions)	16
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2020-21 (incl. under co-pay prescriptions)	17
Table 13	Number of PBS Approved Suppliers, 30 June 2021	18
Table 14	PBS Brand Premiums, 2020-21	18
Table 15(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2020-21	19
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2020-21	19
Table 16(a)	PBS/RPBS Medicines Supplied under Continued Dispensing (ongoing measure only) by Dispensing Pharmacy State, 2020-21	20
Table 16(b)	PBS/RPBS Continued Dispensing (ongoing measure only) Medicines Government Cost by Dispensing Pharmacy State, 2020-21	20
Table 16(c)	PBS/RPBS Medicines Supplied under Continued Dispensing (both Ongoing and Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2020-21	21
Table 16(d)	PBS/RPBS Continued Dispensing (both Ongoing and Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2020-21	21
<b>Supplement 1</b>	<b>Community Pharmacy Agreement (CPA) Expenses</b>	
Table 17	Remuneration for Community Pharmacies and Friendly Societies, 2020-21 (excl. under co-pay prescriptions)	22
Table 18	CPA Professional Pharmacy Programs Expenditure, 2020-21	23
Table 19	Actual Costs of Major Components of CPA, 2020-21	24
Table 20	Community Services Obligation (CSO) Expenditure, 2020-21	24
<b>Supplement 2</b>	<b>PBS Information Line Report, 2020-21</b>	25
<b>Supplement 3</b>	<b>National Diabetes Services Scheme (NDSS)</b>	26
<b>Supplement 4</b>	<b>Historical PBS Prescriptions and Expenditure</b>	
Table 21(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2020-21)	28
Table 21(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2020-21)	30

**Table 1(a): PBS Expense on an Accrual Accounting Basis, 2019-20 and 2020-21**

Category	2019-20	Percentage of Total	2020-21	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$6,433,841,718	51.0%	\$6,884,024,680	50.1%	\$450,182,962	7.0%
Section 85 - General	\$2,262,546,970	17.9%	\$2,405,632,262	17.5%	\$143,085,292	6.3%
Doctor's Bag	\$18,745,817	0.1%	\$16,685,943	0.1%	-\$2,059,874	-11.0%
Section 100*	\$3,886,499,581	30.8%	\$4,429,279,015	32.2%	\$542,779,434	14.0%
Safety Net Cards	\$12,070,996	0.1%	\$15,034,724	0.1%	\$2,963,728	24.6%
<b>Total</b>	<b>\$12,613,705,082</b>	<b>100.0%</b>	<b>\$13,750,656,624</b>	<b>100.0%</b>	<b>\$1,136,951,542</b>	<b>9.0%</b>
Total Including Revenue	\$9,828,680,554		\$10,270,867,025		\$442,186,471	4.5%

\*Individual S100 programs are shown in Table 1(b).

**Table 1(b): PBS Section 100 Programs on an Accrual Accounting Basis, 2019-20 and 2020-21**

Category	2019-20	Percentage of Total	2020-21	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$1,964,880,851	50.6%	\$2,102,049,020	47.5%	\$137,168,169	7.0%
Chemotherapy (EFC & Chemotherapy-related)	\$1,597,332,043	41.1%	\$1,895,181,306	42.8%	\$297,849,263	18.6%
In Vitro Fertilisation	\$115,483,460	3.0%	\$157,416,057	3.6%	\$41,932,597	36.3%
Opiate Dependence Treatment Program	\$70,649,486	1.8%	\$90,681,291	2.0%	\$20,031,805	28.4%
Aboriginal Health Services (GST exclusive)	\$51,321,189	1.3%	\$50,012,059	1.1%	-\$1,309,130	-2.6%
Botulinum Toxin Program (incl. Dysport)	\$54,336,889	1.4%	\$68,154,459	1.5%	\$13,817,570	25.4%
Growth Hormone	\$31,903,234	0.8%	\$34,352,692	0.8%	\$2,449,459	7.7%
Paraplegic and Quadriplegic Program	\$393,060	0.0%	\$227,038	0.0%	-\$166,022	-42.2%
Continuing Medication Program	\$199,369	0.0%	\$138,601	0.0%	-\$60,768	-30.5%
Closing the Gap (CTG) PBS Co-payment Program*	\$0	0.0%	\$31,066,492	0.7%	\$31,066,492	
<b>Total</b>	<b>\$3,886,499,581</b>	<b>100.0%</b>	<b>\$4,429,279,015</b>	<b>100.0%</b>	<b>\$542,779,434</b>	<b>14.0%</b>

**Note:**

Expense figures refer to payments made through the Services Australia and directly from the Department of Health Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on [www.pbs.gov.au](http://www.pbs.gov.au).

\* Figures include expenditure from 1 January 2021 onwards. Prior to this date funding for the CTG PBS Co-payment Program was provided under the Indigenous Australians' Health Programme, Bill 1 Appropriation

**Table 2(a): PBS Prescriptions, 2019-20 and 2020-21**

Section 85 and S100, including Drs Bag and under co-payment prescriptions

Patient Category	2019-20		2020-21		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	149,717,706	71.8%	144,098,300	67.5%	-5,619,406	-3.8%
Concessional Safety Net	40,398,035	19.4%	50,743,086	23.8%	10,345,051	25.6%
<b>Total Concessional</b>	<b>190,115,741</b>	<b>91.2%</b>	<b>194,841,386</b>	<b>91.2%</b>	<b>4,725,645</b>	<b>2.5%</b>
General Non-Safety Net	15,346,614	7.4%	15,552,528	7.3%	205,914	1.3%
General Safety Net	2,601,350	1.2%	2,813,685	1.3%	212,335	8.2%
<b>Total General</b>	<b>17,947,964</b>	<b>8.6%</b>	<b>18,366,213</b>	<b>8.6%</b>	<b>418,249</b>	<b>2.3%</b>
Doctors Bag	418,651	0.2%	360,456	0.2%	-58,195	-13.9%
<b>Total (Over Co-payment)</b>	<b>208,482,356</b>	<b>100.0%</b>	<b>213,568,055</b>	<b>100.0%</b>	<b>5,085,699</b>	<b>2.4%</b>
Under Co-payment	96,378,870		93,590,025		-2,788,845	-2.9%
<b>Total (Over and Under Co-payment)</b>	<b>304,861,226</b>		<b>307,158,080</b>		<b>2,296,854</b>	<b>0.8%</b>

**Table 2(b): PBS Government Cost, 2019-20 and 2020-21**

Section 85 and S100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	2019-20		2020-21		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$6,745,979,625	53.9%	\$7,010,646,005	51.7%	\$264,666,380	3.9%
Concessional Safety Net	\$1,507,311,525	12.1%	\$1,985,329,594	14.6%	\$478,018,070	31.7%
<b>Total Concessional</b>	<b>\$8,253,291,150</b>	<b>66.0%</b>	<b>\$8,995,975,600</b>	<b>66.3%</b>	<b>\$742,684,450</b>	<b>9.0%</b>
General Non-Safety Net	\$4,108,768,751	32.9%	\$4,414,990,093	32.5%	\$306,221,343	7.5%
General Safety Net	\$127,950,181	1.0%	\$147,503,450	1.1%	\$19,553,269	15.3%
<b>Total General</b>	<b>\$4,236,718,932</b>	<b>33.9%</b>	<b>\$4,562,493,543</b>	<b>33.6%</b>	<b>\$325,774,612</b>	<b>7.7%</b>
Doctors Bag	\$16,850,372	0.1%	\$14,971,053	0.1%	-\$1,879,319	-11.2%
<b>Total (Over Co-payment)</b>	<b>\$12,506,860,454</b>	<b>100.0%</b>	<b>\$13,573,440,196</b>	<b>100.0%</b>	<b>\$1,066,579,742</b>	<b>8.5%</b>

**Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2019-20 and 2020-21**

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2019-20		2020-21		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	5,888,275	73%	5,105,131	67%	-783,144	-13.3%
Repatriation Safety Net	2,205,427	27%	2,544,457	33%	339,030	15.4%
<b>Total Repatriation</b>	<b>8,093,702</b>	<b>100%</b>	<b>7,649,588</b>	<b>100%</b>	<b>-444,114</b>	<b>-5.5%</b>

**Table 2(d): RPBS and PBS Government Cost for DVA patients, 2019-20 and 2020-21**

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2019-20		2020-21		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$242,649,543	76%	\$236,230,083	72%	-\$6,419,460	-2.6%
Repatriation Safety Net	\$75,395,871	24%	\$91,952,795	28%	\$16,556,923	22.0%
<b>Total Repatriation</b>	<b>\$318,045,415</b>	<b>100%</b>	<b>\$328,182,878</b>	<b>100%</b>	<b>\$10,137,463</b>	<b>3.2%</b>

**Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21**  
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2020-21	Concessional Non-Safety Net	142,641,141	\$4,966,909,221	\$911,124,052	\$5,878,033,273	\$41.21
	Concessional Safety Net	50,569,557	\$1,787,793,797	\$0	\$1,787,793,797	\$35.35
	<b>Total Concessional</b>	<b>193,210,698</b>	<b>\$6,754,703,018</b>	<b>\$911,124,052</b>	<b>\$7,665,827,070</b>	<b>\$39.68</b>
	General Non-Safety Net	13,965,778	\$2,247,741,985	\$521,358,291	\$2,769,100,276	\$198.28
	General Safety Net	2,787,346	\$119,462,970	\$17,799,421	\$137,262,392	\$49.24
	<b>Total General</b>	<b>16,753,124</b>	<b>\$2,367,204,956</b>	<b>\$539,157,712</b>	<b>\$2,906,362,668</b>	<b>\$173.48</b>
	<b>Total (excluding Drs Bag)</b>	<b>209,963,822</b>	<b>\$9,121,907,974</b>	<b>\$1,450,281,764</b>	<b>\$10,572,189,738</b>	<b>\$50.35</b>
	Doctors Bag	360,456	\$14,971,053	\$0	\$14,971,053	\$41.53
	<b>Total (including Drs Bag)</b>	<b>210,324,278</b>	<b>\$9,136,879,027</b>	<b>\$1,450,281,764</b>	<b>\$10,587,160,791</b>	<b>\$50.34</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21**  
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2020-21	Concessional Non-Safety Net	144,098,300	\$7,010,646,005	\$917,783,821	\$7,928,429,826	\$55.02
	Concessional Safety Net	50,743,086	\$1,985,329,594	\$0	\$1,985,329,594	\$39.13
	<b>Total Concessional</b>	<b>194,841,386</b>	<b>\$8,995,975,600</b>	<b>\$917,783,821</b>	<b>\$9,913,759,421</b>	<b>\$50.88</b>
	General Non-Safety Net	15,552,528	\$4,414,990,093	\$568,519,553	\$4,983,509,646	\$320.43
	General Safety Net	2,813,685	\$147,503,450	\$17,923,996	\$165,427,446	\$58.79
	<b>Total General</b>	<b>18,366,213</b>	<b>\$4,562,493,543</b>	<b>\$586,443,549</b>	<b>\$5,148,937,092</b>	<b>\$280.35</b>
	<b>Total (excluding Drs Bag)</b>	<b>213,207,599</b>	<b>\$13,558,469,143</b>	<b>\$1,504,227,370</b>	<b>\$15,062,696,513</b>	<b>\$70.65</b>
	Doctors Bag	360,456	\$14,971,053	\$0	\$14,971,053	\$41.53
	<b>Total (including Drs Bag)</b>	<b>213,568,055</b>	<b>\$13,573,440,196</b>	<b>\$1,504,227,370</b>	<b>\$15,077,667,566</b>	<b>\$70.60</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2019-20 and 2020-21**  
Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Ave. Price**
2019	Jul	17,911,281	8,503,660	26,414,941	\$1,062,527,428	\$134,453,512	\$1,196,980,940	\$66.83
	Aug	17,751,698	8,456,974	26,208,672	\$1,034,514,824	\$126,007,997	\$1,160,522,820	\$65.38
	Sep	17,014,678	7,923,736	24,938,414	\$1,010,380,566	\$113,621,428	\$1,124,001,994	\$66.06
	Oct	18,303,574	8,156,780	26,460,354	\$1,089,644,385	\$111,610,748	\$1,201,255,133	\$65.63
	Nov	17,863,866	7,763,408	25,627,274	\$1,061,774,746	\$103,108,326	\$1,164,883,072	\$65.21
	Dec	19,943,415	7,856,558	27,799,973	\$1,134,003,489	\$101,741,651	\$1,235,745,140	\$61.96
2020	Jan	15,248,676	7,972,684	23,221,360	\$957,845,344	\$133,913,289	\$1,091,758,632	\$71.60
	Feb	15,568,873	7,992,694	23,561,567	\$949,921,429	\$136,568,017	\$1,086,489,446	\$69.79
	Mar	19,868,028	10,409,661	30,277,689	\$1,176,633,496	\$180,253,710	\$1,356,887,206	\$68.30
	Apr	15,432,746	6,665,828	22,098,574	\$950,645,248	\$126,607,084	\$1,077,252,332	\$69.80
	May	16,142,938	7,226,272	23,369,210	\$999,198,432	\$126,963,487	\$1,126,161,919	\$69.76
	Jun	17,013,932	7,450,608	24,464,540	\$1,062,920,694	\$125,064,316	\$1,187,985,010	\$69.82
<b>Total</b>		<b>208,063,705</b>	<b>96,378,863</b>	<b>304,442,568</b>	<b>\$12,490,010,081</b>	<b>\$1,519,913,564</b>	<b>\$14,009,923,645</b>	<b>\$67.33</b>
2020	Jul	18,347,966	7,914,418	26,262,384	\$1,161,634,886	\$126,732,980	\$1,288,367,866	\$70.22
	Aug	17,674,851	7,649,174	25,324,025	\$1,108,819,354	\$114,306,183	\$1,223,125,537	\$69.20
	Sep	18,024,051	7,445,193	25,469,244	\$1,162,833,013	\$108,375,455	\$1,271,208,468	\$70.53
	Oct	18,582,747	7,552,806	26,135,553	\$1,160,260,413	\$105,120,448	\$1,265,380,861	\$68.09
	Nov	18,360,514	7,342,257	25,702,771	\$1,158,901,043	\$98,355,605	\$1,257,256,648	\$68.48
	Dec	21,392,256	7,613,507	29,005,763	\$1,292,384,420	\$100,600,833	\$1,392,985,252	\$65.12
2021	Jan	14,987,763	7,541,059	22,528,822	\$980,684,213	\$132,818,162	\$1,113,502,374	\$74.29
	Feb	15,633,408	7,401,864	23,035,272	\$1,017,177,163	\$137,449,853	\$1,154,627,016	\$73.86
	Mar	18,217,402	8,485,769	26,703,171	\$1,201,423,191	\$158,786,479	\$1,360,209,670	\$74.67
	Apr	16,780,554	7,868,818	24,649,372	\$1,049,371,275	\$142,479,242	\$1,191,850,517	\$71.03
	May	17,469,082	8,399,785	25,868,867	\$1,114,742,856	\$143,040,290	\$1,257,783,146	\$72.00
	Jun	17,737,005	8,375,363	26,112,368	\$1,150,237,317	\$136,161,839	\$1,286,399,156	\$72.53
<b>Total</b>		<b>213,207,599</b>	<b>93,590,013</b>	<b>306,797,612</b>	<b>\$13,558,469,143</b>	<b>\$1,504,227,370</b>	<b>\$15,062,696,513</b>	<b>\$70.65</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2020-21**

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

<b>PBS S85 subsidised prescriptions</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	45,742,518	35,391,819	29,944,060	12,076,539	13,321,814	4,116,529	555,134	1,492,728	142,641,141
Concessional Safety Net	17,274,830	12,205,926	10,403,112	4,259,326	4,318,107	1,504,633	90,031	513,592	50,569,557
General Non-Safety Net	4,556,381	3,284,855	2,901,067	903,429	1,543,047	321,513	137,174	318,312	13,965,778
General Safety Net	977,502	658,403	509,711	186,521	311,438	55,183	9,179	79,409	2,787,346
<b>Total</b>	<b>68,551,231</b>	<b>51,541,003</b>	<b>43,757,950</b>	<b>17,425,815</b>	<b>19,494,406</b>	<b>5,997,858</b>	<b>791,518</b>	<b>2,404,041</b>	<b>209,963,822</b>
<b>PBS (S85 + S100) subsidised prescriptions</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	46,180,362	35,759,930	30,252,841	12,190,385	13,464,088	4,155,386	566,006	1,529,302	144,098,300
Concessional Safety Net	17,326,007	12,255,118	10,440,032	4,271,637	4,334,083	1,509,522	90,472	516,215	50,743,086
General Non-Safety Net	5,080,621	3,680,008	3,179,917	1,005,592	1,714,654	347,576	152,440	391,720	15,552,528
General Safety Net	983,370	667,177	516,430	187,665	314,388	55,506	9,237	79,912	2,813,685
<b>Total</b>	<b>69,570,360</b>	<b>52,362,233</b>	<b>44,389,220</b>	<b>17,655,279</b>	<b>19,827,213</b>	<b>6,067,990</b>	<b>818,155</b>	<b>2,517,149</b>	<b>213,207,599</b>
<b>Government Cost (\$85 only)</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	\$1,620,137,955	\$1,204,696,768	\$1,039,217,182	\$412,868,837	\$470,115,797	\$145,061,879	\$18,916,496	\$55,894,308	\$4,966,909,221
Concessional Safety Net	\$604,597,754	\$432,533,881	\$364,062,837	\$149,012,676	\$158,823,505	\$55,982,703	\$2,947,101	\$19,833,340	\$1,787,793,797
General Non-Safety Net	\$723,323,760	\$596,323,608	\$411,141,809	\$150,667,136	\$244,898,362	\$55,319,967	\$15,205,677	\$50,861,667	\$2,247,741,985
General Safety Net	\$40,755,125	\$28,959,430	\$21,006,965	\$7,957,718	\$14,289,769	\$2,628,549	\$337,802	\$3,527,612	\$119,462,970
<b>Total</b>	<b>\$2,988,814,595</b>	<b>\$2,262,513,687</b>	<b>\$1,835,428,794</b>	<b>\$720,506,367</b>	<b>\$888,127,432</b>	<b>\$258,993,097</b>	<b>\$37,407,077</b>	<b>\$130,116,927</b>	<b>\$9,121,907,974</b>
<b>Government Cost (\$85 + S100)</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	\$2,226,074,318	\$1,696,129,152	\$1,511,542,425	\$582,594,118	\$674,467,500	\$204,471,156	\$29,777,740	\$85,589,596	\$7,010,646,005
Concessional Safety Net	\$653,888,115	\$484,958,178	\$410,995,629	\$167,353,070	\$179,089,852	\$63,906,999	\$3,097,450	\$22,040,301	\$1,985,329,594
General Non-Safety Net	\$1,457,035,858	\$1,112,875,736	\$817,960,521	\$292,989,070	\$493,170,897	\$93,672,975	\$35,282,994	\$112,002,042	\$4,414,990,093
General Safety Net	\$47,004,169	\$37,746,099	\$27,462,193	\$9,739,379	\$17,768,027	\$3,172,975	\$383,166	\$4,227,442	\$147,503,450
<b>Total</b>	<b>\$4,384,002,459</b>	<b>\$3,331,709,165</b>	<b>\$2,767,960,769</b>	<b>\$1,052,675,636</b>	<b>\$1,364,496,276</b>	<b>\$365,224,106</b>	<b>\$68,541,351</b>	<b>\$223,859,381</b>	<b>\$13,558,469,143</b>
<b>Total Cost (\$85 + S100)*</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	\$2,518,164,338	\$1,929,250,313	\$1,701,745,997	\$660,661,498	\$759,773,978	\$230,731,692	\$32,634,576	\$95,467,433	\$7,928,429,826
Concessional Safety Net	\$653,888,115	\$484,958,178	\$410,995,629	\$167,353,070	\$179,089,852	\$63,906,999	\$3,097,450	\$22,040,301	\$1,985,329,594
General Non-Safety Net	\$1,639,255,979	\$1,256,388,005	\$929,009,679	\$330,032,524	\$556,207,930	\$105,846,302	\$39,502,776	\$127,266,452	\$4,983,509,646
General Safety Net	\$53,245,300	\$42,096,456	\$30,692,675	\$10,937,596	\$19,760,686	\$3,518,597	\$431,696	\$4,744,440	\$165,427,446
<b>Total</b>	<b>\$4,864,553,732</b>	<b>\$3,712,692,952</b>	<b>\$3,072,443,981</b>	<b>\$1,168,984,688</b>	<b>\$1,514,832,446</b>	<b>\$404,003,590</b>	<b>\$75,666,498</b>	<b>\$249,518,626</b>	<b>\$15,062,696,513</b>
<b>Population Percentage</b>	<b>NSW</b>	<b>VIC</b>	<b>QLD</b>	<b>SA</b>	<b>WA</b>	<b>TAS</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Population**	8,169,114	6,657,142	5,193,269	1,770,309	2,669,996	541,209	246,453	431,190	25,683,372
PBS S85 Subsidised Scripts per Capita	8.39	7.74	8.43	9.84	7.30	11.08	3.21	5.58	8.18
PBS (S85 + S100) Subsidised Scripts per Capita	8.52	7.87	8.55	9.97	7.43	11.21	3.32	5.84	8.30
PBS S85 Govt Cost per Capita	\$365.87	\$339.86	\$353.42	\$406.99	\$332.63	\$478.55	\$151.78	\$301.76	\$355.17
PBS (S85 + S100) Govt Cost per Capita	\$536.66	\$500.47	\$532.99	\$594.63	\$511.05	\$674.83	\$278.11	\$519.17	\$527.91
Population Percentage	31.81%	25.92%	20.22%	6.89%	10.40%	2.11%	0.96%	1.68%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.63%	24.56%	20.82%	8.28%	9.30%	2.85%	0.38%	1.18%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.33%	24.57%	20.41%	7.76%	10.06%	2.69%	0.51%	1.65%	100.00%
Total Cost Percentage	32.30%	24.65%	20.40%	7.76%	10.06%	2.68%	0.50%	1.66%	100.00%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

\*\*Population 31 December 2020, Source: ABS Publication 3101.04

**Table 5(a): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21**  
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	349,789	\$425,114,369	\$5,389,467	\$430,503,836	\$1,230.75
2	PEMBROLIZUMAB	48,058	\$417,541,353	\$215,995	\$417,757,348	\$8,692.77
3	NIVOLUMAB	48,994	\$389,305,206	\$227,663	\$389,532,869	\$7,950.62
4	ADALIMUMAB	272,918	\$295,374,832	\$7,563,345	\$302,938,177	\$1,110.00
5	DENOSUMAB	937,305	\$256,166,578	\$10,935,511	\$267,102,089	\$284.97
6	USTEKINUMAB	35,283	\$245,074,777	\$1,045,684	\$246,120,461	\$6,975.61
7	APIXABAN	2,913,163	\$238,986,510	\$33,311,036	\$272,297,547	\$93.47
8	LENALIDOMIDE	39,622	\$216,334,172	\$747,023	\$217,081,195	\$5,478.80
9	RANIBIZUMAB	180,171	\$209,791,569	\$2,432,133	\$212,223,702	\$1,177.90
10	OCRELIZUMAB	10,084	\$175,223,838	\$329,573	\$175,553,411	\$17,409.10
11	SOFOSBUVIR + VELPATASVIR	13,639	\$171,763,831	\$277,043	\$172,040,874	\$12,613.89
12	GLECAPREVIR + PIBRENTASVIR	9,127	\$170,911,357	\$240,653	\$171,152,010	\$18,752.27
13	RIVAROXABAN	2,250,190	\$151,170,991	\$30,578,823	\$181,749,814	\$80.77
14	IBRUTINIB	15,593	\$143,799,896	\$215,491	\$144,015,387	\$9,235.90
15	TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	6,547	\$130,515,687	\$107,944	\$130,623,630	\$19,951.68
16	LUMACAFTOR + IVACAFTOR	7,266	\$129,328,761	\$90,589	\$129,419,351	\$17,811.64
17	FINGOLIMOD	52,919	\$116,415,587	\$1,446,179	\$117,861,766	\$2,227.21
18	FERRIC CARBOXYMALTOSSE	419,294	\$109,965,133	\$11,095,819	\$121,060,952	\$288.73
19	ENZALUTAMIDE	30,968	\$109,116,081	\$356,270	\$109,472,352	\$3,535.02
20	ATEZOLIZUMAB	14,556	\$108,209,134	\$85,017	\$108,294,151	\$7,439.83
21	ETANERCEPT	104,026	\$107,570,017	\$2,368,600	\$109,938,617	\$1,056.84
22	IPILIMUMAB	4,291	\$103,971,831	\$45,141	\$104,016,972	\$24,240.73
23	ROSUVASTATIN	8,590,929	\$96,493,553	\$43,567,139	\$140,060,692	\$16.30
24	TRASTUZUMAB	61,654	\$94,929,587	\$765,553	\$95,695,141	\$1,552.13
25	INFLIXIMAB	67,048	\$94,652,499	\$2,249,504	\$96,902,002	\$1,445.26
26	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	51,440	\$91,433,842	\$1,480,908	\$92,914,750	\$1,806.27
27	BEVACIZUMAB	46,159	\$90,264,834	\$275,650	\$90,540,485	\$1,961.49
28	GOLIMUMAB	72,133	\$89,360,236	\$1,929,811	\$91,290,047	\$1,265.58
29	VEDOLIZUMAB	28,564	\$87,304,174	\$937,412	\$88,241,586	\$3,089.26
30	SECUKINUMAB	59,330	\$84,060,095	\$1,627,910	\$85,688,005	\$1,444.26
31	FLUTICASON PROPIONATE + SALMETEROL	2,101,731	\$83,420,445	\$37,322,728	\$120,743,173	\$57.45
32	SACUBITRIL + VALSARTAN	437,592	\$83,194,549	\$5,646,669	\$88,841,218	\$203.02
33	ESOMEPRAZOLE	5,775,259	\$82,988,074	\$27,576,178	\$110,564,252	\$19.14
34	TOFACITINIB	66,230	\$82,428,110	\$1,366,440	\$83,794,550	\$1,265.21
35	PALIPERIDONE	233,908	\$79,563,910	\$2,360,648	\$81,924,558	\$350.24
36	ATORVASTATIN	7,882,131	\$79,187,549	\$38,580,142	\$117,767,690	\$14.94
37	PALBOCICLIB	18,227	\$76,843,945	\$355,476	\$77,199,421	\$4,235.44
38	DARBEPOETIN ALFA	69,580	\$74,432,272	\$958,383	\$75,390,656	\$1,083.51
39	CLADRIBINE	4,595	\$74,003,204	\$112,170	\$74,115,374	\$16,129.57
40	PREGABALIN	3,255,607	\$72,806,152	\$15,307,758	\$88,113,909	\$27.07
41	DURVALUMAB	10,912	\$70,305,811	\$42,752	\$70,348,563	\$6,446.90
42	INSULIN GLARGINE	341,390	\$69,632,776	\$4,781,356	\$74,414,132	\$217.97
43	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,930,536	\$67,812,589	\$37,089,397	\$104,901,985	\$54.34
44	RUXOLITINIB	14,028	\$67,635,175	\$223,923	\$67,859,098	\$4,837.40
45	RITUXIMAB	40,250	\$66,431,844	\$360,144	\$66,791,988	\$1,659.43
46	RIBOCICLIB	14,262	\$65,687,127	\$279,482	\$65,966,610	\$4,625.34
47	IVACAFTOR	2,988	\$64,089,794	\$48,711	\$64,138,505	\$21,465.36
48	OXYCODONE + NALOXONE	1,561,710	\$64,080,264	\$10,060,149	\$74,140,413	\$47.47
49	FOLLITROPIN ALFA	52,951	\$63,951,506	\$2,047,526	\$65,999,032	\$1,246.42
50	ARIPRAZOLE	388,414	\$63,114,905	\$4,786,595	\$67,901,500	\$174.82

\* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 5(b): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2020-21**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ROSUVASTATIN	8,590,929	\$96,493,553	\$43,567,139	\$140,060,692	\$16.30
2	ATORVASTATIN	7,882,131	\$79,187,549	\$38,580,142	\$117,767,690	\$14.94
3	PANTOPRAZOLE	6,397,332	\$61,968,912	\$30,212,546	\$92,181,458	\$14.41
4	ESOMEPRAZOLE	5,775,259	\$82,988,074	\$27,576,178	\$110,564,252	\$19.14
5	PERINDOPRIL	4,158,808	\$42,185,575	\$21,135,885	\$63,321,459	\$15.23
6	METFORMIN	3,470,403	\$40,316,798	\$15,497,772	\$55,814,571	\$16.08
7	PREGABALIN	3,255,607	\$72,806,152	\$15,307,758	\$88,113,909	\$27.07
8	AMLODIPINE	2,985,564	\$25,199,895	\$14,583,782	\$39,783,678	\$13.33
9	APIXABAN	2,913,163	\$238,986,510	\$33,311,036	\$272,297,547	\$93.47
10	SALBUTAMOL	2,839,092	\$47,228,626	\$11,572,593	\$58,801,219	\$20.71
11	IRBESARTAN	2,703,737	\$25,987,996	\$13,515,935	\$39,503,931	\$14.61
12	TELMISARTAN	2,456,837	\$24,859,729	\$12,838,610	\$37,698,339	\$15.34
13	SERTRALINE	2,379,145	\$22,094,855	\$12,472,442	\$34,567,297	\$14.53
14	ESCITALOPRAM	2,340,573	\$22,062,378	\$12,499,571	\$34,561,949	\$14.77
15	CANDESARTAN	2,330,736	\$22,968,196	\$11,960,276	\$34,928,472	\$14.99
16	CEFALEXIN	2,278,858	\$21,267,093	\$11,871,574	\$33,138,668	\$14.54
17	RIVAROXABAN	2,250,190	\$151,170,991	\$30,578,823	\$181,749,814	\$80.77
18	MIRTAZAPINE	2,221,057	\$25,523,150	\$10,481,905	\$36,005,055	\$16.21
19	PARACETAMOL + CODEINE	2,160,361	\$38,395,317	\$11,914,834	\$50,310,151	\$23.29
20	RAMIPRIL	2,137,632	\$20,341,434	\$10,453,549	\$30,794,983	\$14.41
21	ATENOLOL	2,125,276	\$19,206,735	\$10,149,821	\$29,356,556	\$13.81
22	FLUTICASONE PROPIONATE + SALMETEROL	2,101,731	\$83,420,445	\$37,322,728	\$120,743,173	\$57.45
23	OXYCODONE	2,051,547	\$48,240,208	\$10,739,947	\$58,980,156	\$28.75
24	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,930,536	\$67,812,589	\$37,089,397	\$104,901,985	\$54.34
25	VENLAFAXINE	1,858,491	\$22,395,124	\$9,467,822	\$31,862,946	\$17.14
26	CLOPIDOGREL	1,836,219	\$21,664,468	\$7,956,135	\$29,620,603	\$16.13
27	METOPROLOL TARTRATE	1,830,777	\$17,551,040	\$8,213,990	\$25,765,030	\$14.07
28	RABEPRAZOLE	1,767,009	\$18,230,832	\$8,468,014	\$26,698,846	\$15.11
29	AMITRIPTYLINE	1,739,186	\$18,368,767	\$7,972,627	\$26,341,393	\$15.15
30	SIMVASTATIN	1,721,868	\$16,099,700	\$8,271,747	\$24,371,447	\$14.15
31	LERCANIDIPINE	1,703,128	\$17,545,887	\$7,968,682	\$25,514,568	\$14.98
32	PARACETAMOL	1,616,754	\$24,142,321	\$5,813,230	\$29,955,550	\$18.53
33	DIAZEPAM	1,614,180	\$13,368,234	\$7,897,838	\$21,266,072	\$13.17
34	PERINDOPRIL + AMLODIPINE	1,573,670	\$18,414,187	\$8,518,257	\$26,932,444	\$17.11
35	OXYCODONE + NALOXONE	1,561,710	\$64,080,264	\$10,060,149	\$74,140,413	\$47.47
36	SITAGLIPTIN + METFORMIN	1,555,315	\$61,064,845	\$25,208,697	\$86,273,542	\$55.47
37	FUROSEMIDE (FRUSEMIDE)	1,516,060	\$14,953,266	\$6,078,312	\$21,031,578	\$13.87
38	BISOPROLOL	1,483,892	\$23,579,295	\$6,744,919	\$30,324,214	\$20.44
39	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,459,705	\$15,408,985	\$7,424,004	\$22,832,989	\$15.64
40	AMOXICILLIN	1,443,534	\$13,415,880	\$8,005,154	\$21,421,034	\$14.84
41	TIOTROPIUM	1,402,287	\$47,731,142	\$12,528,271	\$60,259,413	\$42.97
42	OMEPRAZOLE	1,388,211	\$16,233,519	\$6,596,121	\$22,829,640	\$16.45
43	DUTASTERIDE + TAMSULOSIN	1,375,805	\$37,103,995	\$6,425,225	\$43,529,220	\$31.64
44	GLICLAZIDE	1,375,768	\$20,497,742	\$5,663,181	\$26,160,923	\$19.02
45	MELOXICAM	1,373,002	\$14,790,987	\$6,822,580	\$21,613,568	\$15.74
46	TRAMADOL	1,315,286	\$19,068,777	\$5,879,177	\$24,947,953	\$18.97
47	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,309,127	\$21,006,905	\$5,357,606	\$26,364,511	\$20.14
48	AMOXICILLIN + CLAVULANIC ACID	1,284,651	\$13,372,635	\$6,725,015	\$20,097,650	\$15.64
49	PREDNISOLONE	1,266,885	\$13,259,208	\$5,856,880	\$19,116,088	\$15.09
50	DESVENLAFAXINE	1,245,139	\$25,169,843	\$8,418,577	\$33,588,420	\$26.98

\* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 5(c): Top 25 PBS Antineoplastic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21**

Section 85 and Section 100, excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	PEMBROLIZUMAB	48,058	\$417,541,353	\$215,995	\$417,757,348	\$8,692.77
2	NIVOLUMAB	48,994	\$389,305,206	\$227,663	\$389,532,869	\$7,950.62
3	LENALIDOMIDE	39,622	\$216,334,172	\$747,023	\$217,081,195	\$5,478.80
4	IBRUTINIB	15,593	\$143,799,896	\$215,491	\$144,015,387	\$9,235.90
5	ENZALUTAMIDE	30,968	\$109,116,081	\$356,270	\$109,472,352	\$3,535.02
6	ATEZOLIZUMAB	14,556	\$108,209,134	\$85,017	\$108,294,151	\$7,439.83
7	IPILIMUMAB	4,291	\$103,971,831	\$45,141	\$104,016,972	\$24,240.73
8	TRASTUZUMAB	61,654	\$94,929,587	\$765,553	\$95,695,141	\$1,552.13
9	BEVACIZUMAB	46,159	\$90,264,834	\$275,650	\$90,540,485	\$1,961.49
10	PALBOCICLIB	18,227	\$76,843,945	\$355,476	\$77,199,421	\$4,235.44
11	DURVALUMAB	10,912	\$70,305,811	\$42,752	\$70,348,563	\$6,446.90
12	RUXOLITINIB	14,028	\$67,635,175	\$223,923	\$67,859,098	\$4,837.40
13	RIBOCICLIB	14,262	\$65,687,127	\$279,482	\$65,966,610	\$4,625.34
14	GOSERELIN^	115,873	\$63,056,702	\$2,613,732	\$65,670,434	\$566.74
15	PERTUZUMAB	18,827	\$61,244,379	\$138,184	\$61,382,562	\$3,260.35
16	OSIMERTINIB	7,704	\$61,152,625	\$153,710	\$61,306,335	\$7,957.73
17	RITUXIMAB^^	36,242	\$58,321,776	\$262,072	\$58,583,848	\$1,616.46
18	OBINUTUZUMAB	10,781	\$58,144,124	\$45,061	\$58,189,184	\$5,397.38
19	DASATINIB	13,255	\$56,968,788	\$343,170	\$57,311,958	\$4,323.80
20	BORTEZOMIB	52,033	\$55,269,135	\$130,389	\$55,399,524	\$1,064.70
21	ABIRATERONE	15,580	\$53,548,911	\$176,515	\$53,725,427	\$3,448.36
22	CARFILZOMIB	22,631	\$53,338,005	\$41,765	\$53,379,770	\$2,358.70
23	LEUPRORELIN^^	47,808	\$49,495,612	\$605,430	\$50,101,043	\$1,047.96
24	POMALIDOMIDE	4,267	\$43,823,894	\$64,739	\$43,888,633	\$10,285.59
25	TRASTUZUMAB EMTANSINE	8,233	\$37,045,191	\$43,041	\$37,088,232	\$4,504.83

\* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Some of the usage may be for treating other conditions.

^^ Excludes PBS items that are not for cancer treatment.

**Table 5(d): Top 25 PBS Biological Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2020-21**

Section 85 and Section 100, excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	349,789	\$425,114,369	\$5,389,467	\$430,503,836	\$1,230.75
2	PEMBROLIZUMAB	48,058	\$417,541,353	\$215,995	\$417,757,348	\$8,692.77
3	NIVOLUMAB	48,994	\$389,305,206	\$227,663	\$389,532,869	\$7,950.62
4	ADALIMUMAB	272,918	\$295,374,832	\$7,563,345	\$302,938,177	\$1,110.00
5	DENOSUMAB	937,305	\$256,166,578	\$10,935,511	\$267,102,089	\$284.97
6	USTEKINUMAB	35,283	\$245,074,777	\$1,045,684	\$246,120,461	\$6,975.61
7	RANIBIZUMAB	180,171	\$209,791,569	\$2,432,133	\$212,223,702	\$1,177.90
8	OCRELIZUMAB	10,084	\$175,223,838	\$329,573	\$175,553,411	\$17,409.10
9	ATEZOLIZUMAB	14,556	\$108,209,134	\$85,017	\$108,294,151	\$7,439.83
10	ETANERCEPT	104,026	\$107,570,017	\$2,368,600	\$109,938,617	\$1,056.84
11	IPILIMUMAB	4,291	\$103,971,831	\$45,141	\$104,016,972	\$24,240.73
12	TRASTUZUMAB	61,654	\$94,929,587	\$765,553	\$95,695,141	\$1,552.13
13	INFLIXIMAB	67,048	\$94,652,499	\$2,249,504	\$96,902,002	\$1,445.26
14	BEVACIZUMAB	46,159	\$90,264,834	\$275,650	\$90,540,485	\$1,961.49
15	GOLIMUMAB	72,133	\$89,360,236	\$1,929,811	\$91,290,047	\$1,265.58
16	VEDOLIZUMAB	28,564	\$87,304,174	\$937,412	\$88,241,586	\$3,089.26
17	SECUKINUMAB	59,330	\$84,060,095	\$1,627,910	\$85,688,005	\$1,444.26
18	DARBEPOETIN ALFA	69,580	\$74,432,272	\$958,383	\$75,390,656	\$1,083.51
19	DURVALUMAB	10,912	\$70,305,811	\$42,752	\$70,348,563	\$6,446.90
20	INSULIN GLARGINE	341,390	\$69,632,776	\$4,781,356	\$74,414,132	\$217.97
21	RITUXIMAB	40,250	\$66,431,844	\$360,144	\$66,791,988	\$1,659.43
22	FOLLITROPIN ALFA	52,951	\$63,951,506	\$2,047,526	\$65,999,032	\$1,246.42
23	PEGFILGRASTIM	72,005	\$61,464,403	\$2,017,641	\$63,482,044	\$881.63
24	PERTUZUMAB	18,827	\$61,244,379	\$138,184	\$61,382,562	\$3,260.35
25	GUSELKUMAB	16,227	\$61,218,384	\$496,067	\$61,714,451	\$3,803.20

\* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 6: Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2020-21**

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
1	ROSUVASTATIN	8,590,929	5,348,616	13,939,545	\$96,493,553
2	ATORVASTATIN	7,882,131	3,560,127	11,442,258	\$79,187,549
3	PANTOPRAZOLE	6,397,332	2,683,470	9,080,802	\$61,968,912
4	ESOMEPRAZOLE	5,775,259	2,411,108	8,186,367	\$82,988,074
5	PERINDOPRIL	4,158,808	2,606,194	6,765,002	\$42,185,575
6	ESCITALOPRAM	2,340,573	3,045,690	5,386,263	\$22,062,378
7	METFORMIN	3,470,403	1,855,461	5,325,864	\$40,316,798
8	SERTRALINE	2,379,145	2,657,637	5,036,782	\$22,094,855
9	CEFALEXIN	2,278,858	2,263,431	4,542,289	\$21,267,093
10	AMLODIPINE	2,985,564	1,390,761	4,376,325	\$25,199,895
11	TELMISARTAN	2,456,837	1,701,145	4,157,982	\$24,859,729
12	IRBESARTAN	2,703,737	1,335,380	4,039,117	\$25,987,996
13	PREGABALIN	3,255,607	782,381	4,037,988	\$72,806,152
14	CANDESARTAN	2,330,736	1,389,635	3,720,371	\$22,968,196
15	SALBUTAMOL	2,839,092	840,228	3,679,320	\$47,228,626
16	AMOXICILLIN	1,443,534	2,082,952	3,526,486	\$13,415,880
17	PARACETAMOL + CODEINE	2,160,361	1,331,979	3,492,340	\$38,395,317
18	VENLAFAXINE	1,858,491	1,477,859	3,336,350	\$22,395,124
19	RAMIPRIL	2,137,632	1,175,932	3,313,564	\$20,341,434
20	OXYCODONE	2,051,547	1,069,203	3,120,750	\$48,240,208
21	MIRTAZAPINE	2,221,057	819,191	3,040,248	\$25,523,150
22	ATENOLOL	2,125,276	822,419	2,947,695	\$19,206,735
23	APIXABAN	2,913,163	845	2,914,008	\$238,986,510
24	PERINDOPRIL + AMLODIPINE	1,573,670	1,269,796	2,843,466	\$18,414,187
25	AMOXICILLIN + CLAVULANIC ACID	1,284,651	1,431,708	2,716,359	\$13,372,635
26	AMITRIPTYLINE	1,739,186	941,198	2,680,384	\$18,368,767
27	RABEPRAZOLE	1,767,009	850,453	2,617,462	\$18,230,832
28	MELOXICAM	1,373,002	1,097,409	2,470,411	\$14,790,987
29	FLUOXETINE	1,155,050	1,302,177	2,457,227	\$15,803,346
30	METOPROLOL TARTRATE	1,830,777	577,855	2,408,632	\$17,551,040
31	DIAZEPAM	1,614,180	762,669	2,376,849	\$13,368,234
32	DESVENLAFAXINE	1,245,139	1,106,509	2,351,648	\$25,169,843
33	LERCANIDIPINE	1,703,128	581,511	2,284,639	\$17,545,887
34	CLOPIDOGREL	1,836,219	417,392	2,253,611	\$21,664,468
35	RIVAROXABAN	2,250,190	1,376	2,251,566	\$151,170,991
36	SIMVASTATIN	1,721,868	473,434	2,195,302	\$16,099,700
37	PREDNISOLONE	1,266,885	915,750	2,182,635	\$13,259,208
38	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,459,705	693,939	2,153,644	\$15,408,985
39	FLUTICASONE PROPIONATE + SALMETEROL	2,101,731	237	2,101,968	\$83,420,445
40	DULOXETINE	1,229,499	793,613	2,023,112	\$17,564,894
41	DOXYCYCLINE	943,222	1,038,913	1,982,135	\$9,194,844
42	BISOPROLOL	1,483,892	479,597	1,963,489	\$23,579,295
43	OMEPRAZOLE	1,388,211	560,266	1,948,477	\$16,233,519
44	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,930,536	11,149	1,941,685	\$67,812,589
45	LEVOTHYROXINE	1,059,296	817,001	1,876,297	\$23,265,492
46	TRAMADOL	1,315,286	528,883	1,844,169	\$19,068,777
47	GLICLAZIDE	1,375,768	458,112	1,833,880	\$20,497,742
48	CELECOXIB	996,391	799,275	1,795,666	\$11,947,001
49	CITALOPRAM	994,539	781,442	1,775,981	\$8,933,399
50	OXYCODONE + NALOXONE	1,561,710	211,583	1,773,293	\$64,080,264

**Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2020-21**  
Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	24,378,287	14,801,735	39,180,022
2	C10	LIPID MODIFYING AGENTS	23,082,425	11,479,856	34,562,281
3	N06	PSYCHOANALEPTICS	18,955,316	14,329,922	33,285,238
4	A02	DRUGS FOR ACID RELATED DISORDERS	15,966,384	6,813,197	22,779,581
5	N02	ANALGESICS	15,922,989	5,461,014	21,384,003
6	J01	ANTIBACTERIALS FOR SYSTEMIC USE	9,094,582	9,729,552	18,824,134
7	A10	DRUGS USED IN DIABETES	13,876,055	2,395,491	16,271,546
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,668,576	1,379,749	13,048,325
9	B01	ANTITHROMBOTIC AGENTS	9,640,245	879,349	10,519,594
10	N05	PSYCHOLEPTICS	7,420,416	1,817,471	9,237,887
11	C08	CALCIUM CHANNEL BLOCKERS	6,575,200	2,618,193	9,193,393
12	C07	BETA BLOCKING AGENTS	6,802,878	2,324,860	9,127,738
13	S01	OPHTHALMOLOGICALS	7,046,407	1,591,535	8,637,942
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,573,174	3,104,306	6,677,480
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,319,657	3,121,866	5,441,523
16	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,405,750	1,733,724	4,139,474
17	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,124,137	1,682,787	3,806,924
18	C01	CARDIAC THERAPY	2,889,725	600,913	3,490,638
19	N03	ANTIEPILEPTICS	2,431,048	752,281	3,183,329
20	C03	DIURETICS	2,512,745	557,204	3,069,949
21	C02	ANTIHYPERTENSIVES	1,990,240	579,824	2,570,064
22	G04	UROLOGICALS	1,917,572	401,795	2,319,367
23	M04	ANTIGOUT PREPARATIONS	1,309,677	856,492	2,166,169
24	M05	DRUGS FOR TREATMENT OF BONE DISEASES	1,876,388	217,906	2,094,294
25	L04	IMMUNOSUPPRESSANTS	1,895,260	141,626	2,036,886
26	H03	THYROID THERAPY	1,168,042	862,345	2,030,387
27	L01	ANTINEOPLASTIC AGENTS	1,929,702	97,737	2,027,439
28	A06	DRUGS FOR CONSTIPATION	1,489,044	83,217	1,572,261
29	N04	ANTI-PARKINSON DRUGS	1,364,468	194,127	1,558,595
30	J05	ANTIVIRALS FOR SYSTEMIC USE	981,532	497,475	1,479,007
31	A04	ANTIEMETICS AND ANTINAUSEANTS	918,126	415,843	1,333,969
32	B03	ANTIANEMIC PREPARATIONS	1,072,183	128,890	1,201,073
33	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	797,932	350,562	1,148,494
34	L02	ENDOCRINE THERAPY	816,544	323,364	1,139,908
35	S02	OTOLOGICALS	552,033	479,170	1,031,203
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	894,425	40,762	935,187
37	N07	OTHER NERVOUS SYSTEM DRUGS	695,171	5,108	700,279
38	D10	ANTI-ACNE PREPARATIONS	267,030	165,775	432,805
39	A12	MINERAL SUPPLEMENTS	334,643	54,432	389,075
40	M03	MUSCLE RELAXANTS	311,489	66,322	377,811
41	D05	ANTIPSORIATICS	276,720	55,701	332,421
42	G02	OTHER GYNECOLOGICALS	224,332	6,315	230,647
43	A11	VITAMINS	147,245	37,558	184,803
44	A09	DIGESTIVES, INCL. ENZYMES	181,562	693	182,255
45	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	176,924	58	176,982
46	L03	IMMUNOSTIMULANTS	159,535	263	159,798
47	D11	OTHER DERMATOLOGICAL PREPARATIONS	75,605	75,945	151,550
48	A01	STOMATOLOGICAL PREPARATIONS	92,902	43,643	136,545
49	B02	ANTIHEMORRHAGICS	84,915	40,315	125,230
50	V03	ALL OTHER THERAPEUTIC PRODUCTS	115,317	9,081	124,398

**Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2019-20 and 2020-21**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2019-20	2020-21	Prescriptions Change	Percentage Change	2019-20	2020-21	Gov Cost Change	Percentage Change	2019-20	2020-21	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	33,042,150	34,751,691	1,709,541	5.2%	\$983,949,400	\$1,085,548,217	\$101,598,816	10.3%	\$269,348,965	\$275,865,574	\$6,516,609	2.4%
BLOOD AND BLOOD FORMING ORGANS	10,389,249	10,798,520	409,271	3.9%	\$754,718,130	\$812,038,229	\$57,320,099	7.6%	\$109,524,862	\$114,392,530	\$4,867,668	4.4%
CARDIOVASCULAR SYSTEM	65,311,793	68,233,130	2,921,337	4.5%	\$977,775,133	\$1,080,248,913	\$102,473,780	10.5%	\$361,519,933	\$350,520,472	-\$10,999,461	-3.0%
DERMATOLOGICALS	2,983,177	3,131,548	148,371	5.0%	\$71,147,557	\$99,076,665	\$27,929,108	39.3%	\$29,030,582	\$30,645,976	\$1,615,395	5.6%
GENITO URINARY SYSTEM AND SEX HORMONES	4,148,784	4,461,561	312,777	7.5%	\$246,648,895	\$296,915,784	\$50,266,889	20.4%	\$39,694,118	\$42,826,961	\$3,132,843	7.9%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,615,505	3,558,069	-57,436	-1.6%	\$180,688,506	\$192,455,360	\$11,766,854	6.5%	\$23,357,380	\$22,824,602	-\$532,778	-2.3%
ANTIINFECTIVES FOR SYSTEMIC USE	11,980,566	10,197,108	-1,783,458	-14.9%	\$983,928,291	\$839,367,395	-\$144,560,895	-14.7%	\$81,968,798	\$70,117,579	-\$11,851,219	-14.5%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	4,510,296	4,801,041	290,745	6.4%	\$5,019,877,152	\$5,647,378,774	\$627,501,622	12.5%	\$70,690,950	\$74,799,739	\$4,108,789	5.8%
MUSCULO-SKELETAL SYSTEM	6,851,656	7,071,229	219,573	3.2%	\$438,820,717	\$472,603,865	\$33,783,148	7.7%	\$44,880,206	\$45,362,883	\$482,677	1.1%
NERVOUS SYSTEM	45,450,717	46,810,989	1,360,272	3.0%	\$1,231,349,889	\$1,297,772,603	\$66,422,714	5.4%	\$291,056,741	\$291,399,759	\$343,019	0.1%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	72,940	65,069	-7,871	-10.8%	\$2,790,693	\$2,987,511	\$196,818	7.1%	\$578,715	\$448,419	-\$130,296	-22.5%
RESPIRATORY SYSTEM	12,397,023	11,761,504	-635,519	-5.1%	\$821,738,594	\$888,965,712	\$67,227,118	8.2%	\$151,519,022	\$138,449,394	-\$13,069,627	-8.6%
SENSORY ORGANS	7,408,422	7,615,611	207,189	2.8%	\$710,539,149	\$779,094,468	\$68,555,318	9.6%	\$42,340,305	\$42,498,817	\$158,512	0.4%
VARIOUS	194,244	191,743	-2,501	-1.3%	\$78,552,585	\$74,571,356	-\$3,981,229	-5.1%	\$3,554,542	\$3,292,327	-\$262,215	-7.4%
UNLESS OTHERWISE CLASSIFIED	125,834	119,242	-6,592	-5.2%	\$4,335,762	\$4,415,344	\$79,582	1.8%	\$848,447	\$782,338	-\$66,110	-7.8%
<b>TOTAL</b>	<b>208,482,356</b>	<b>213,568,055</b>	<b>5,085,699</b>	<b>2.4%</b>	<b>\$12,506,860,454</b>	<b>\$13,573,440,196</b>	<b>\$1,066,579,742</b>	<b>8.5%</b>	<b>\$1,519,913,564</b>	<b>\$1,504,227,370</b>	<b>-\$15,686,194</b>	<b>-1.0%</b>

ATC Group Level 1	Total Cost*				Average Price**			
	2019-20	2020-21	Total Cost Change	Percentage Change	2019-20	2020-21	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$1,253,298,365	\$1,361,413,791	\$108,115,425	8.6%	\$37.93	\$39.18	\$1.25	3.3%
BLOOD AND BLOOD FORMING ORGANS	\$864,242,992	\$926,430,760	\$62,187,767	7.2%	\$83.19	\$85.79	\$2.60	3.1%
CARDIOVASCULAR SYSTEM	\$1,339,295,066	\$1,430,769,386	\$91,474,320	6.8%	\$20.51	\$20.97	\$0.46	2.2%
DERMATOLOGICALS	\$100,178,139	\$129,722,641	\$29,544,502	29.5%	\$33.58	\$41.42	\$7.84	23.3%
GENITO URINARY SYSTEM AND SEX HORMONES	\$286,343,013	\$339,742,745	\$53,399,732	18.6%	\$69.02	\$76.15	\$7.13	10.3%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$204,045,886	\$215,279,962	\$11,234,076	5.5%	\$56.44	\$60.50	\$4.06	7.2%
ANTIINFECTIVES FOR SYSTEMIC USE	\$1,065,897,089	\$909,484,974	-\$156,412,115	-14.7%	\$88.97	\$89.19	\$0.22	0.2%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$5,090,568,101	\$5,722,178,512	\$631,610,411	12.4%	\$1,128.65	\$1,191.86	\$63.21	5.6%
MUSCULO-SKELETAL SYSTEM	\$483,700,923	\$517,966,748	\$34,265,825	7.1%	\$70.60	\$73.25	\$2.65	3.8%
NERVOUS SYSTEM	\$1,522,406,630	\$1,589,172,362	\$66,765,733	4.4%	\$33.50	\$33.95	\$0.45	1.3%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$3,369,408	\$3,435,929	\$66,522	2.0%	\$46.19	\$52.80	\$6.61	14.3%
RESPIRATORY SYSTEM	\$973,257,616	\$1,027,415,106	\$54,157,491	5.6%	\$78.51	\$87.35	\$8.84	11.3%
SENSORY ORGANS	\$752,879,454	\$821,593,285	\$68,713,830	9.1%	\$101.62	\$107.88	\$6.26	6.2%
VARIOUS	\$82,107,127	\$77,863,683	-\$4,243,444	-5.2%	\$422.70	\$406.08	-\$16.62	-3.9%
UNLESS OTHERWISE CLASSIFIED	\$5,184,210	\$5,197,682	\$13,472	0.3%	\$41.20	\$43.59	\$2.39	5.8%
<b>TOTAL</b>	<b>\$14,026,774,017</b>	<b>\$15,077,667,566</b>	<b>\$1,050,893,548</b>	<b>7.5%</b>	<b>\$67.28</b>	<b>\$70.60</b>	<b>\$3.32</b>	<b>4.9%</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 9(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2019-20 and 2020-21**  
 Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2019-20					2020-21					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	PEMBROLIZUMAB	37,565	\$331,455,964	\$166,297	\$331,622,261	\$8,828	48,058	\$417,541,353	\$215,995	\$417,757,348	\$8,693	\$86,085,388	25.97%
2	TEZACAFTOR + IVACAFTOR (& IVACAFTOR	2,711	\$55,411,086	\$45,684	\$55,456,770	\$20,456	6,547	\$130,515,687	\$107,944	\$130,623,630	\$19,952	\$75,104,601	135.54%
3	NIVOLUMAB	50,321	\$333,953,984	\$236,197	\$334,190,181	\$6,641	48,994	\$389,305,206	\$227,663	\$389,532,869	\$7,951	\$55,351,221	16.57%
4	AFLIBERCEPT	299,956	\$372,846,671	\$4,562,079	\$377,408,750	\$1,258	349,789	\$425,114,369	\$5,389,467	\$430,503,836	\$1,231	\$52,267,698	14.02%
5	LENALIDOMIDE	28,132	\$165,774,004	\$457,070	\$166,231,074	\$5,909	39,622	\$216,334,172	\$747,023	\$217,081,195	\$5,479	\$50,560,169	30.50%
6	DURVALUMAB	3,526	\$22,845,330	\$15,559	\$22,860,888	\$6,484	10,912	\$70,305,811	\$42,752	\$70,348,563	\$6,447	\$47,460,481	207.75%
7	ATEZOLIZUMAB	8,232	\$61,979,194	\$49,557	\$62,028,751	\$7,535	14,556	\$108,209,134	\$85,017	\$108,294,151	\$7,440	\$46,229,940	74.59%
8	APIXABAN	2,480,259	\$201,271,374	\$29,246,027	\$230,517,401	\$93	2,913,163	\$238,986,510	\$33,311,036	\$272,297,547	\$93	\$37,715,136	18.74%
9	USTEKINUMAB	29,392	\$209,733,381	\$885,599	\$210,618,980	\$7,166	35,283	\$245,074,777	\$1,045,684	\$246,120,461	\$6,976	\$35,341,396	16.85%
10	OCRELIZUMAB	8,132	\$140,297,834	\$261,435	\$140,559,270	\$17,285	10,084	\$175,223,838	\$329,573	\$175,553,411	\$17,409	\$34,926,003	24.89%
11	UPADACITINIB	464	\$578,166	\$10,089	\$588,255	\$1,268	28,060	\$35,202,450	\$627,322	\$35,829,772	\$1,277	\$34,624,284	5,988.64%
12	OSIMERTINIB	3,710	\$29,618,302	\$67,889	\$29,686,190	\$8,002	7,704	\$61,152,625	\$153,710	\$61,306,335	\$7,958	\$31,534,323	106.47%
13	PALBOCICLIB	11,318	\$47,713,397	\$239,724	\$47,953,121	\$4,237	18,227	\$76,843,945	\$355,476	\$77,199,421	\$4,235	\$29,130,548	61.05%
14	RISANKIZUMAB	1,153	\$6,147,320	\$36,257	\$6,183,577	\$5,363	5,359	\$28,745,985	\$166,746	\$28,912,731	\$5,395	\$22,598,665	367.62%
15	SACUBITRIL + VALSARTAN	336,887	\$62,346,613	\$4,494,229	\$66,840,841	\$198	437,592	\$83,194,549	\$5,646,669	\$88,841,218	\$203	\$20,847,936	33.44%
16	DULAGLUTIDE	382,657	\$43,118,955	\$6,817,820	\$49,936,776	\$131	541,628	\$62,890,116	\$8,691,050	\$71,581,166	\$132	\$19,771,161	45.85%
17	FERRIC CARBOXYMALTOSE	334,898	\$90,350,554	\$8,577,318	\$98,927,873	\$295	419,294	\$109,965,133	\$11,095,819	\$121,060,952	\$289	\$19,614,579	21.71%
18	DENOSUMAB	857,148	\$236,845,054	\$10,261,086	\$247,106,140	\$288	937,305	\$256,166,578	\$10,935,511	\$267,102,089	\$285	\$19,321,524	8.16%
19	VENETOCLAX	2,168	\$15,110,078	\$41,479	\$15,151,557	\$6,989	4,847	\$34,342,455	\$84,873	\$34,427,328	\$7,103	\$19,232,377	127.28%
20	GUSELKUMAB	11,342	\$42,596,049	\$355,373	\$42,951,422	\$3,787	16,227	\$61,218,384	\$496,067	\$61,714,451	\$3,803	\$18,622,335	43.72%
21	VEDOLIZUMAB	22,241	\$68,863,100	\$721,377	\$69,584,476	\$3,129	28,564	\$87,304,174	\$937,412	\$88,241,586	\$3,089	\$18,441,075	26.78%
22	TRASTUZUMAB EMTANSINE	4,483	\$19,591,148	\$21,955	\$19,613,103	\$4,375	8,233	\$37,045,191	\$43,041	\$37,088,232	\$4,505	\$17,454,044	89.09%
23	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	41,961	\$74,145,281	\$1,245,903	\$75,391,184	\$1,797	51,440	\$91,433,842	\$1,480,908	\$92,914,750	\$1,806	\$17,288,560	23.32%
24	FOLLITROPIN ALFA	40,407	\$47,233,496	\$1,561,347	\$48,794,843	\$1,208	52,951	\$63,951,506	\$2,047,526	\$65,999,032	\$1,246	\$16,718,009	35.39%
25	BENRALIZUMAB	8,115	\$27,019,246	\$191,230	\$27,210,476	\$3,353	13,116	\$43,731,848	\$287,622	\$44,019,470	\$3,356	\$16,712,602	61.85%
26	OBINUTUZUMAB	7,662	\$41,793,996	\$31,277	\$41,825,273	\$5,459	10,781	\$58,144,124	\$45,061	\$58,189,184	\$5,397	\$16,350,127	39.12%
27	INSULIN DEGLUDEC + INSULIN ASPART	96,038	\$33,775,416	\$1,250,741	\$35,026,157	\$365	133,481	\$47,939,616	\$1,585,109	\$49,524,725	\$371	\$14,164,200	41.94%
28	OMALIZUMAB	40,773	\$38,819,551	\$1,049,584	\$39,869,135	\$978	54,011	\$52,096,397	\$1,386,339	\$53,482,736	\$990	\$13,276,846	34.20%
29	BOTULINUM TOXIN TYPE A	84,278	\$49,522,534	\$2,350,609	\$51,873,143	\$616	102,955	\$62,357,915	\$2,845,601	\$65,203,516	\$633	\$12,835,381	25.92%
30	SECUKINUMAB	51,904	\$72,221,939	\$1,454,620	\$73,676,559	\$1,419	59,330	\$84,060,095	\$1,627,910	\$85,688,005	\$1,444	\$11,838,157	16.39%
31	BINIMETINIB	280	\$2,007,201	\$6,657	\$2,013,858	\$7,192	1,919	\$13,798,975	\$41,501	\$13,840,475	\$7,212	\$11,791,774	587.47%
32	PANTOPRAZOLE	5,691,557	\$50,479,313	\$28,531,882	\$79,011,194	\$14	6,397,332	\$61,968,912	\$30,212,546	\$92,181,458	\$14	\$11,489,599	22.76%
33	IXEKIZUMAB	9,871	\$33,358,800	\$301,261	\$33,660,061	\$3,410	13,145	\$44,624,991	\$383,749	\$45,008,740	\$3,424	\$11,266,191	33.77%
34	ENCORAFENIB	282	\$1,936,933	\$6,671	\$1,943,603	\$6,892	1,917	\$13,015,684	\$41,259	\$13,056,943	\$6,811	\$11,078,752	571.97%
35	ATORVASTATIN	7,540,488	\$68,411,838	\$39,224,619	\$107,636,457	\$14	7,882,131	\$79,187,549	\$38,580,142	\$117,767,690	\$15	\$10,775,711	15.75%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 9(b): Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2019-20 and 2020-21**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2019-20					2020-21					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	ROSUVASTATIN	7,800,754	\$94,491,710	\$41,712,812	\$136,204,522	\$17.46	8,590,929	\$96,493,553	\$43,567,139	\$140,060,692	\$16.30	790,175	10.13%
2	PANTOPRAZOLE	5,691,557	\$50,479,313	\$28,531,882	\$79,011,194	\$13.88	6,397,332	\$61,968,912	\$30,212,546	\$92,181,458	\$14.41	705,775	12.40%
3	APIXABAN	2,480,259	\$201,271,374	\$29,246,027	\$230,517,401	\$92.94	2,913,163	\$238,986,510	\$33,311,036	\$272,297,547	\$93.47	432,904	17.45%
4	ATORVASTATIN	7,540,488	\$68,411,838	\$39,224,619	\$107,636,457	\$14.27	7,882,131	\$79,187,549	\$38,580,142	\$117,767,690	\$14.94	341,643	4.53%
5	AMLODIPINE	2,675,848	\$19,883,662	\$13,896,993	\$33,780,654	\$12.62	2,985,564	\$25,199,895	\$14,583,782	\$39,783,678	\$13.33	309,716	11.57%
6	ESCITALOPRAM	2,089,766	\$17,933,588	\$11,521,455	\$29,455,043	\$14.09	2,340,573	\$22,062,378	\$12,499,571	\$34,561,949	\$14.77	250,807	12.00%
7	SERTRALINE	2,153,901	\$18,036,276	\$11,669,429	\$29,705,705	\$13.79	2,379,145	\$22,094,855	\$12,472,442	\$34,567,297	\$14.53	225,244	10.46%
8	TELMISARTAN	2,247,642	\$20,727,629	\$12,325,060	\$33,052,690	\$14.71	2,456,837	\$24,859,729	\$12,838,610	\$37,698,339	\$15.34	209,195	9.31%
9	EMPAGLIFLOZIN	857,706	\$38,517,068	\$14,084,377	\$52,601,445	\$61.33	1,057,690	\$46,956,679	\$16,531,207	\$63,487,886	\$60.03	199,984	23.32%
10	MIRTAZAPINE	2,037,339	\$21,800,536	\$10,125,393	\$31,925,928	\$15.67	2,221,057	\$25,523,150	\$10,481,905	\$36,005,055	\$16.21	183,718	9.02%
11	PERINDOPRIL	3,981,014	\$36,727,115	\$21,317,759	\$58,044,874	\$14.58	4,158,808	\$42,185,575	\$21,135,885	\$63,321,459	\$15.23	177,794	4.47%
12	METFORMIN	3,299,714	\$35,161,835	\$15,794,877	\$50,956,712	\$15.44	3,470,403	\$40,316,798	\$15,497,772	\$55,814,571	\$16.08	170,689	5.17%
13	ESOMEPRAZOLE	5,605,491	\$76,807,914	\$28,374,643	\$105,182,557	\$18.76	5,775,259	\$82,988,074	\$27,576,178	\$110,564,252	\$19.14	169,768	3.03%
14	RIVAROXABAN	2,083,960	\$149,939,742	\$29,242,171	\$179,181,913	\$85.98	2,250,190	\$151,170,991	\$30,578,823	\$181,749,814	\$80.77	166,230	7.98%
15	BISOPROLOL	1,318,729	\$19,797,852	\$6,459,866	\$26,257,717	\$19.91	1,483,892	\$23,579,295	\$6,744,919	\$30,324,214	\$20.44	165,163	12.52%
16	DUTASTERIDE + TAMSULOSIN	1,215,850	\$33,041,223	\$6,086,519	\$39,127,743	\$32.18	1,375,805	\$37,103,995	\$6,425,225	\$43,529,220	\$31.64	159,955	13.16%
17	DULAGLUTIDE	382,657	\$43,118,955	\$6,817,820	\$49,936,776	\$130.50	541,628	\$62,890,116	\$8,691,050	\$71,581,166	\$132.16	158,971	41.54%
18	CANDESARTAN	2,174,257	\$19,471,860	\$11,740,036	\$31,211,896	\$14.36	2,330,736	\$22,968,196	\$11,960,276	\$34,928,472	\$14.99	156,479	7.20%
19	EMPAGLIFLOZIN + METFORMIN	663,000	\$29,750,979	\$12,777,793	\$42,528,773	\$64.15	807,581	\$35,771,640	\$14,966,385	\$50,738,025	\$62.83	144,581	21.81%
20	PERINDOPRIL + AMLODIPINE	1,441,273	\$15,705,000	\$8,111,688	\$23,816,688	\$16.52	1,573,670	\$18,414,187	\$8,518,257	\$26,932,444	\$17.11	132,397	9.19%
21	LISDEXAMFETAMINE	336,056	\$32,132,197	\$7,444,344	\$39,576,541	\$117.77	466,817	\$40,701,911	\$10,970,404	\$51,672,315	\$110.69	130,761	38.91%
22	DULOXETINE	1,102,609	\$14,866,253	\$5,597,272	\$20,463,525	\$18.56	1,229,499	\$17,564,894	\$5,942,689	\$23,507,583	\$19.12	126,890	11.51%
23	VENLAFAXINE	1,739,404	\$19,561,515	\$9,245,600	\$28,807,115	\$16.56	1,858,491	\$22,395,124	\$9,467,822	\$31,862,946	\$17.14	119,087	6.85%
24	FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL	393,458	\$34,203,828	\$3,813,396	\$38,017,223	\$96.62	511,643	\$43,720,428	\$4,709,978	\$48,430,406	\$94.66	118,185	30.04%
25	TELMISARTAN + AMLODIPINE	689,802	\$7,397,894	\$3,927,061	\$11,324,955	\$16.42	805,265	\$9,290,593	\$4,409,434	\$13,700,027	\$17.01	115,463	16.74%
26	AMITRIPTYLINE	1,625,239	\$15,718,626	\$7,883,036	\$23,601,662	\$14.52	1,739,186	\$18,368,767	\$7,972,627	\$26,341,393	\$15.15	113,947	7.01%
27	FLUOXETINE	1,045,542	\$13,416,072	\$5,826,569	\$19,242,641	\$18.40	1,155,050	\$15,803,346	\$6,291,381	\$22,094,727	\$19.13	109,508	10.47%
28	METHYLPHENIDATE	757,660	\$27,911,977	\$13,407,707	\$41,319,684	\$54.54	863,319	\$32,984,082	\$15,640,629	\$48,624,711	\$56.32	105,659	13.95%
29	HYALURONATE SODIUM	312,004	\$9,247,317	\$1,485,177	\$10,732,494	\$34.40	417,140	\$12,691,819	\$1,854,629	\$14,546,448	\$34.87	105,136	33.70%
30	LINAGLIPTIN	564,309	\$27,931,086	\$5,871,766	\$33,802,853	\$59.90	668,398	\$33,755,144	\$6,654,007	\$40,409,151	\$60.46	104,089	18.45%
31	TAPENTADOL	819,400	\$27,776,425	\$6,597,171	\$34,373,595	\$41.95	921,880	\$32,100,309	\$7,119,171	\$39,219,480	\$42.54	102,480	12.51%
32	SACUBITRIL + VALSARTAN	336,887	\$62,346,613	\$4,494,229	\$66,840,841	\$198.41	437,592	\$83,194,549	\$5,646,669	\$88,841,218	\$203.02	100,705	29.89%
33	DEXAMETHASONE	282,305	\$12,035,852	\$1,556,024	\$13,591,877	\$48.15	376,903	\$15,127,128	\$2,080,977	\$17,208,104	\$45.66	94,598	33.51%
34	FERRIC CARBOXYMALTOSE	334,898	\$90,350,554	\$8,577,318	\$98,927,873	\$295.40	419,294	\$109,965,133	\$11,095,819	\$121,060,952	\$288.73	84,396	25.20%
35	DENOSUMAB	857,148	\$236,845,054	\$10,261,086	\$247,106,140	\$288.29	937,305	\$256,166,578	\$10,935,511	\$267,102,089	\$284.97	80,157	9.35%

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.


\*\* Average Price is Total Cost divided by PBS Subsidised Prescriptions.

\*\*\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 10(a): PBS Section 85 Prescription Volume, 2017-18 to 2020-21**

Section 85 only, including Drs Bag and under co-payment prescriptions


Prescription Type	2017-18	2018-19	2019-20	2020-21
Over Co-payment	201,433,842	202,303,105	205,490,328	210,324,278
Under Co-payment	89,436,834	93,869,122	96,326,008	93,537,811
<b>Total</b>	<b>290,870,676</b>	<b>296,172,227</b>	<b>301,816,336</b>	<b>303,862,089</b>



**Table 10(b): PBS Section 85 expenditure, 2017-18 to 2020-21**

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2017-18	2018-19	2019-20	2020-21
Government Cost	\$8,463,709,127	\$8,211,599,852	\$8,552,639,115	\$9,136,879,027
Patient Contribution*	\$1,415,450,126	\$1,440,199,923	\$1,471,111,060	\$1,450,281,764
<b>Total Cost**</b>	<b>\$9,879,159,253</b>	<b>\$9,651,799,774</b>	<b>\$10,023,750,175</b>	<b>\$10,587,160,791</b>



\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

\*\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

**Table 11: PBS Prescriptions and Government Cost by Formulary, 2020-21**

Section 85 and Section 100, including under co-payment prescriptions and Drs Bag

Formulary Group <sup>1</sup>	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	26,408,586	2,813,547	29,222,133	9.5%	\$8,209,424,267	60.5%
F2	177,133,737	89,925,395	267,059,132	86.9%	\$4,217,673,645	31.1%
Combination Drugs <sup>2</sup>	9,900,484	820,039	10,720,523	3.5%	\$1,141,763,839	8.4%
Other <sup>3</sup>	125,248	31,044	156,292	0.1%	\$4,578,446	0.0%
<b>Total</b>	<b>213,568,055</b>	<b>93,590,025</b>	<b>307,158,080</b>	<b>100.0%</b>	<b>\$13,573,440,196</b>	<b>100.0%</b>

**Notes:**

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2.  
Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands.  
Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply.  
Allocation to F1 or F2 is determined by legislative instrument.
2. Combination Drugs are not allocated to any formulary.
3. The category 'Other' includes extemporaneously prepared items.

**Table 12(a): Top 20 Responsible Persons by Total Cost, 2020-21**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,896,362	1,594,504	6,490,866	<b>\$1,025,061,419</b>	\$46,683,676	\$1,071,745,095	\$891,201,264
2	JANSSEN-CILAG PTY LTD	2,020,834	364,723	2,385,557	<b>\$890,665,605</b>	\$23,823,400	\$914,489,005	\$765,338,085
3	ALPHAPHARM PTY LTD	38,455,619	19,272,625	57,728,244	<b>\$576,527,648</b>	\$196,792,211	\$773,319,859	\$349,811,422
4	APOTEX PTY LTD	37,547,078	16,223,597	53,770,675	<b>\$503,628,356</b>	\$187,542,332	\$691,170,688	\$268,567,363
5	BAYER AUSTRALIA LTD	3,256,732	910,216	4,166,948	<b>\$639,087,008</b>	\$46,381,461	\$685,468,469	\$587,010,722
6	ABBVIE PTY LTD	350,786	13	350,799	<b>\$637,775,397</b>	\$8,988,440	\$646,763,837	\$596,313,477
7	ASTRAZENECA PTY LTD	9,106,277	3,018,253	12,124,530	<b>\$448,432,606</b>	\$95,539,694	\$543,972,300	\$387,403,849
8	PFIZER AUSTRALIA PTY LTD	3,048,527	1,500,889	4,549,416	<b>\$403,464,898</b>	\$36,342,440	\$439,807,339	\$369,415,624
9	BOEHRINGER INGELHEIM PTY LTD	8,012,148	1,657,574	9,669,722	<b>\$329,969,631</b>	\$82,991,670	\$412,961,301	\$303,134,711
10	ROCHE PRODUCTS PTY LTD	889,110	178,265	1,067,375	<b>\$395,439,557</b>	\$8,786,099	\$404,225,656	\$344,174,793
11	AMGEN AUSTRALIA PTY LIMITED	1,059,187	45	1,059,232	<b>\$370,173,448</b>	\$13,146,701	\$383,320,149	\$308,068,815
12	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,047,044	1,034	3,048,078	<b>\$334,052,093</b>	\$36,015,197	\$370,067,290	\$306,599,500
13	GILEAD SCIENCES PTY LIMITED	131,820	-	131,820	<b>\$366,089,908</b>	\$3,722,981	\$369,812,888	\$313,193,307
14	SANDOZ PTY LTD	16,474,878	16,996,266	33,471,144	<b>\$276,292,187</b>	\$93,023,226	\$369,315,414	\$207,241,808
15	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,270,808	994,414	7,265,222	<b>\$276,821,508</b>	\$70,790,602	\$347,612,110	\$230,614,375
16	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.	16,801	-	16,801	<b>\$323,934,242</b>	\$247,244	\$324,181,485	\$313,063,734
17	ARROW PHARMA PTY LTD	17,015,612	7,144,582	24,160,194	<b>\$232,427,832</b>	\$85,487,102	\$317,914,935	\$130,922,756
18	SANOFI-AVENTIS AUSTRALIA PTY LTD	7,470,623	3,044,884	10,515,507	<b>\$241,727,638</b>	\$47,043,243	\$288,770,880	\$189,784,997
19	CELGENE PTY LIMITED	47,025	-	47,025	<b>\$265,257,012</b>	\$864,729	\$266,121,741	\$183,689,697
20	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,435,590	587,326	3,022,916	<b>\$203,101,404</b>	\$27,536,001	\$230,637,405	\$159,682,949

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2020-21**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	38,455,619	19,272,625	57,728,244	\$576,527,648	\$196,792,211	\$773,319,859	\$349,811,422
2	APOTEX PTY LTD	37,547,078	16,223,597	53,770,675	\$503,628,356	\$187,542,332	\$691,170,688	\$268,567,363
3	ARROW PHARMA PTY LTD	17,015,612	7,144,582	24,160,194	\$232,427,832	\$85,487,102	\$317,914,935	\$130,922,756
4	SANDOZ PTY LTD	16,474,878	16,996,266	33,471,144	\$276,292,187	\$93,023,226	\$369,315,414	\$207,241,808
5	ASTRAZENECA PTY LTD	9,106,277	3,018,253	12,124,530	\$448,432,606	\$95,539,694	\$543,972,300	\$387,403,849
6	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	8,872,526	5,884,488	14,757,014	\$141,477,009	\$48,935,903	\$190,412,912	\$108,407,355
7	BOEHRINGER INGELHEIM PTY LTD	8,012,148	1,657,574	9,669,722	\$329,969,631	\$82,991,670	\$412,961,301	\$303,134,711
8	SANOFI-AVENTIS AUSTRALIA PTY LTD	7,470,623	3,044,884	10,515,507	\$241,727,638	\$47,043,243	\$288,770,880	\$189,784,997
9	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,270,808	994,414	7,265,222	\$276,821,508	\$70,790,602	\$347,612,110	\$230,614,375
10	UPJOHN AUSTRALIA PTY LTD	5,880,419	3,191,971	9,072,390	\$86,829,535	\$28,684,003	\$115,513,538	\$55,750,162
11	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,896,362	1,594,504	6,490,866	\$1,025,061,419	\$46,683,676	\$1,071,745,095	\$891,201,264
12	MUNDIPHARMA PTY LIMITED	3,983,085	497,357	4,480,442	\$184,984,524	\$29,671,022	\$214,655,546	\$143,648,228
13	MYLAN HEALTH PTY LTD	3,446,515	1,383,884	4,830,399	\$83,752,257	\$18,327,810	\$102,080,068	\$65,822,897
14	BAYER AUSTRALIA LTD	3,256,732	910,216	4,166,948	\$639,087,008	\$46,381,461	\$685,468,469	\$587,010,722
15	PFIZER AUSTRALIA PTY LTD	3,048,527	1,500,889	4,549,416	\$403,464,898	\$36,342,440	\$439,807,339	\$369,415,624
16	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,047,044	1,034	3,048,078	\$334,052,093	\$36,015,197	\$370,067,290	\$306,599,500
17	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	2,826,773	276,800	3,103,573	\$167,358,116	\$40,005,247	\$207,363,363	\$149,695,023
18	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,435,590	587,326	3,022,916	\$203,101,404	\$27,536,001	\$230,637,405	\$159,682,949
19	SERVIER LABORATORIES (AUST.) PTY. LTD.	2,123,473	1,199,290	3,322,763	\$44,288,659	\$11,454,725	\$55,743,384	\$33,598,126
20	JANSSEN-CILAG PTY LTD	2,020,834	364,723	2,385,557	\$890,665,605	\$23,823,400	\$914,489,005	\$765,338,085

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2020-21**

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	38,455,619	19,272,625	57,728,244	\$576,527,648	\$196,792,211	\$773,319,859	\$349,811,422
2	APOTEX PTY LTD	37,547,078	16,223,597	53,770,675	\$503,628,356	\$187,542,332	\$691,170,688	\$268,567,363
3	SANDOZ PTY LTD	16,474,878	16,996,266	33,471,144	\$276,292,187	\$93,023,226	\$369,315,414	\$207,241,808
4	ARROW PHARMA PTY LTD	17,015,612	7,144,582	24,160,194	\$232,427,832	\$85,487,102	\$317,914,935	\$130,922,756
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	8,872,526	5,884,488	14,757,014	\$141,477,009	\$48,935,903	\$190,412,912	\$108,407,355
6	ASTRAZENECA PTY LTD	9,106,277	3,018,253	12,124,530	\$448,432,606	\$95,539,694	\$543,972,300	\$387,403,849
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	7,470,623	3,044,884	10,515,507	\$241,727,638	\$47,043,243	\$288,770,880	\$189,784,997
8	BOEHRINGER INGELHEIM PTY LTD	8,012,148	1,657,574	9,669,722	\$329,969,631	\$82,991,670	\$412,961,301	\$303,134,711
9	UPJOHN AUSTRALIA PTY LTD	5,880,419	3,191,971	9,072,390	\$86,829,535	\$28,684,003	\$115,513,538	\$55,750,162
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,270,808	994,414	7,265,222	\$276,821,508	\$70,790,602	\$347,612,110	\$230,614,375
11	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,896,362	1,594,504	6,490,866	\$1,025,061,419	\$46,683,676	\$1,071,745,095	\$891,201,264
12	MYLAN HEALTH PTY LTD	3,446,515	1,383,884	4,830,399	\$83,752,257	\$18,327,810	\$102,080,068	\$65,822,897
13	PFIZER AUSTRALIA PTY LTD	3,048,527	1,500,889	4,549,416	\$403,464,898	\$36,342,440	\$439,807,339	\$369,415,624
14	MUNDIPHARMA PTY LIMITED	3,983,085	497,357	4,480,442	\$184,984,524	\$29,671,022	\$214,655,546	\$143,648,228
15	BAYER AUSTRALIA LTD	3,256,732	910,216	4,166,948	\$639,087,008	\$46,381,461	\$685,468,469	\$587,010,722
16	SERVIER LABORATORIES (AUST.) PTY. LTD.	2,123,473	1,199,290	3,322,763	\$44,288,659	\$11,454,725	\$55,743,384	\$33,598,126
17	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	2,826,773	276,800	3,103,573	\$167,358,116	\$40,005,247	\$207,363,363	\$149,695,023
18	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,047,044	1,034	3,048,078	\$334,052,093	\$36,015,197	\$370,067,290	\$306,599,500
19	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,435,590	587,326	3,022,916	\$203,101,404	\$27,536,001	\$230,637,405	\$159,682,949
20	JANSSEN-CILAG PTY LTD	2,020,834	364,723	2,385,557	\$890,665,605	\$23,823,400	\$914,489,005	\$765,338,085

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

\*\* Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

\*\*\* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

**Table 13: Number of PBS Approved Suppliers, 30 June 2021**

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,912	48	-	1
VIC	1,403	38	70	1
QLD	1,187	39	52	-
SA	459	11	15	1
WA	639	6	21	4
TAS	155	5	4	2
NT	40	1	6	-
ACT	80	5	-	-
<b>Total</b>	<b>5,875</b>	<b>153</b>	<b>168</b>	<b>9</b>

**Table 14: PBS Brand Premiums, 2020-21**

Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

	2020-21
Number of brands listed on the PBS <sup>(a)</sup>	5,375
Number of brands with a premium <sup>(a)</sup>	365
% of brands with a premium	6.8%
Average brand premium	\$5.04
Weighted average brand premium <sup>(b)</sup>	\$4.32
Brand premium range	\$0.50 to \$35.30
Prescriptions (millions) dispensed with a brand premium	34.9
Prescriptions (millions) dispensed at the benchmark level <sup>(c)</sup>	136.3
% of prescriptions dispensed at benchmark level	79.6%

**Notes:**

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2021 PBS Schedule.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

**Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2020-21**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

	Concessional		General		RPBS		Total	
Prescription Type	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	48,452,938	25%	5,200,560	30%	1,107,722	15%	54,761,220	25%
Non-Discounted	144,074,462	75%	11,911,695	70%	6,383,171	85%	162,369,328	75%
<b>Total</b>	<b>192,527,400</b>	<b>100%</b>	<b>17,112,255</b>	<b>100%</b>	<b>7,490,893</b>	<b>100%</b>	<b>217,130,548</b>	<b>100%</b>

**Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2020-21**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

	Concessional		General		RPBS		Total	
Discount Range	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	47,317,875	97.7%	5,118,955	98.4%	1,076,671	97.2%	53,513,501	97.7%
0.50 - < \$1.00	721,446	1.5%	48,002	0.9%	17,538	1.6%	786,986	1.4%
< 50c	261,081	0.5%	18,182	0.3%	8,548	0.8%	287,811	0.5%
Other	152,536	0.3%	15,421	0.3%	4,965	0.4%	172,922	0.3%
<b>Total</b>	<b>48,452,938</b>	<b>100.0%</b>	<b>5,200,560</b>	<b>100.0%</b>	<b>1,107,722</b>	<b>100.0%</b>	<b>54,761,220</b>	<b>100.0%</b>

**Table 16(a): PBS/RPBS Medicines Supplied under Continued Dispensing by Dispensing Pharmacy State, 2020-21**

Section 85, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	9,845	6,387	2,160	1,111	2,521	891	32	727	23,674
FLUVASTATIN	28	9	-	-	-	-	-	-	37
LEVONORGESTREL	165	75	77	23	88	33	-	29	490
LEVONORGESTREL + ETHINYLESTRADIOL	2,566	1,749	1,016	487	766	585	8	278	7,455
NORETHISTERONE	117	55	19	11	36	12	-	13	263
NORETHISTERONE + ETHINYLESTRADIOL	38	17	10	8	7	8	-	-	88
NORETHISTERONE + MESTRANOL	-	10	-	-	-	-	-	-	10
PRAVASTATIN	667	337	126	63	162	44	-	47	1,446
ROSUVASTATIN	12,308	7,089	2,480	1,288	2,515	1,153	8	687	27,528
SIMVASTATIN	1,930	1,436	311	216	380	220	6	161	4,660
<b>Total</b>	<b>27,664</b>	<b>17,164</b>	<b>6,199</b>	<b>3,207</b>	<b>6,475</b>	<b>2,946</b>	<b>54</b>	<b>1,942</b>	<b>65,651</b>

**Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2020-21**

Section 85, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$72,550	\$47,769	\$15,631	\$8,133	\$17,699	\$6,436	\$154	\$3,887	\$172,260
FLUVASTATIN	\$791	\$366	\$0	\$0	\$0	\$0	\$0	\$0	\$1,157
LEVONORGESTREL	\$2,360	\$243	\$461	\$66	\$223	\$125	\$0	\$212	\$3,689
LEVONORGESTREL + ETHINYLESTRADIOL	\$7,804	\$5,401	\$2,450	\$1,405	\$2,029	\$2,094	\$23	\$307	\$21,513
NORETHISTERONE	\$1,477	\$607	\$319	\$166	\$421	\$227	\$0	\$173	\$3,390
NORETHISTERONE + ETHINYLESTRADIOL	\$231	\$71	\$63	\$28	\$14	\$14	\$0	\$0	\$421
NORETHISTERONE + MESTRANOL	\$0	\$75	\$0	\$0	\$0	\$0	\$0	\$0	\$75
PRAVASTATIN	\$5,563	\$3,170	\$1,106	\$508	\$1,289	\$387	\$0	\$358	\$12,382
ROSUVASTATIN	\$91,645	\$52,034	\$17,417	\$9,729	\$17,159	\$8,548	\$34	\$3,310	\$199,875
SIMVASTATIN	\$14,771	\$11,053	\$2,356	\$1,728	\$2,614	\$1,706	\$37	\$1,033	\$35,300
<b>Total</b>	<b>\$197,192</b>	<b>\$120,789</b>	<b>\$39,803</b>	<b>\$21,763</b>	<b>\$41,449</b>	<b>\$19,537</b>	<b>\$249</b>	<b>\$9,280</b>	<b>\$450,063</b>

Note:

Includes medicines listed under National Health (Continued Dispensing) Determination 2012 legislation, dispensed under ongoing or emergency measures.

Excludes other medicines covered by Continued Dispensing Arrangements expansion (Emergency Measures) from January 2020. For more information, please see Table 16(c) and 16(d).

Small cells with counts less than 6 are suppressed and removed from the total.

**Table 16(c): PBS/RPBS Medicines Supplied under Continued Dispensing (Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2020-21**

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	35,671	21,183	6,954	3,196	7,907	2,509	29	2,517	79,966
ANTIINFECTIVES FOR SYSTEMIC USE	2,326	1,275	523	218	503	140	-	180	5,165
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1,976	1,093	349	167	455	170	-	194	4,404
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	36	8	29	-	-	-	-	-	73
BLOOD AND BLOOD FORMING ORGANS	9,436	5,064	1,880	879	1,961	601	-	629	20,450
CARDIOVASCULAR SYSTEM	91,955	55,529	18,246	9,821	20,372	8,415	134	5,875	210,347
DERMATOLOGICALS	1,274	811	211	104	344	97	-	105	2,946
GENITO URINARY SYSTEM AND SEX HORMONES	6,256	3,899	1,807	890	1,980	964	10	550	16,356
MUSCULO-SKELETAL SYSTEM	7,842	3,640	1,519	647	1,866	663	11	457	16,645
NERVOUS SYSTEM	38,938	22,775	10,700	4,146	10,703	4,346	50	3,416	95,074
RESPIRATORY SYSTEM	10,697	6,205	2,737	1,208	2,401	1,049	13	893	25,203
SENSORY ORGANS	5,450	2,897	1,007	441	1,174	384	-	259	11,612
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	4,161	2,251	903	386	1,110	403	7	320	9,541
VARIOUS	123	51	24	-	8	21	-	6	233
<b>TOTAL</b>	<b>216,141</b>	<b>126,681</b>	<b>46,889</b>	<b>22,103</b>	<b>50,784</b>	<b>19,762</b>	<b>254</b>	<b>15,401</b>	<b>498,015</b>

**Table 16(d): PBS/RPBS Continued Dispensing Medicines (Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2020-21**

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$1,108,509	\$604,623	\$185,180	\$84,431	\$204,163	\$64,088	\$806	\$55,851	\$2,307,651
ANTIINFECTIVES FOR SYSTEMIC USE	\$144,576	\$18,405	\$8,986	\$3,461	\$6,687	\$1,827	\$0	\$3,137	\$187,079
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$939,493	\$283,179	\$88,581	\$39,684	\$77,065	\$35,879	\$0	\$69,942	\$1,533,823
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$1,706	\$115	\$888	\$0	\$0	\$0	\$0	\$0	\$2,709
BLOOD AND BLOOD FORMING ORGANS	\$439,071	\$222,124	\$77,203	\$38,267	\$79,461	\$23,951	\$0	\$27,128	\$907,204
CARDIOVASCULAR SYSTEM	\$892,714	\$533,284	\$173,707	\$92,606	\$182,701	\$73,776	\$598	\$47,137	\$1,996,522
DERMATOLOGICALS	\$28,408	\$16,205	\$4,228	\$1,749	\$6,148	\$1,981	\$0	\$1,767	\$60,486
GENITO URINARY SYSTEM AND SEX HORMONES	\$68,283	\$40,646	\$14,736	\$6,656	\$18,585	\$6,798	\$23	\$3,998	\$159,726
MUSCULO-SKELETAL SYSTEM	\$308,885	\$52,244	\$23,269	\$12,233	\$22,997	\$9,668	\$53	\$6,248	\$435,596
NERVOUS SYSTEM	\$577,680	\$341,597	\$340,735	\$52,165	\$113,925	\$60,379	\$368	\$48,831	\$1,535,679
RESPIRATORY SYSTEM	\$349,743	\$206,102	\$76,472	\$33,966	\$72,790	\$30,361	\$292	\$24,047	\$793,774
SENSORY ORGANS	\$526,534	\$49,602	\$19,003	\$9,269	\$19,332	\$6,850	\$0	\$3,388	\$633,979
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$60,490	\$31,307	\$13,351	\$5,552	\$14,657	\$5,006	\$50	\$3,779	\$134,192
VARIOUS	\$24,630	\$11,880	\$3,936	\$0	\$2,812	\$1,579	\$0	\$583	\$45,419
<b>TOTAL</b>	<b>\$5,470,720</b>	<b>\$2,411,312</b>	<b>\$1,030,275</b>	<b>\$380,040</b>	<b>\$821,324</b>	<b>\$322,142</b>	<b>\$2,191</b>	<b>\$295,835</b>	<b>\$10,733,839</b>

**Note:**

Continued Dispensing Emergency Measures came into effect on 13 January 2020.

Includes medicines listed under National Health (Continued Dispensing – Emergency Measures) Determination 2020, dispensed under ongoing or emergency measures.

Small cells with counts less than 6 are suppressed and removed from the total.

**Table 17: Remuneration for Community Pharmacies and Friendly Societies<sup>1</sup> for PBS subsidised prescriptions, 2019-20 to 2020-21**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2019-20	2020-21
<b>Price to Pharmacists</b>			
	Ex-Manufacturer Price	\$6,962,682,865	\$7,362,814,544
	Wholesale Mark-up	\$409,523,060	\$425,185,142
	<b>Sub total</b>	<b>\$7,372,205,925</b>	<b>\$7,787,999,685</b>
<b>Administration, Handling and Storage Costs</b>			
	AHI fee*	\$990,743,919	\$1,125,735,385
	<b>Sub total</b>	<b>\$990,743,919</b>	<b>\$1,125,735,385</b>
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up		
<b>Pharmacist's Specialised Skills in Dispensing the Medicines</b>			
	Dispensing Fee	\$1,557,293,775	\$1,669,577,633
	Dangerous Drug Fee	\$25,569,359	\$40,634,218
	Wastage	\$3,137,198	\$4,292,312
	Container Fee	\$666,944	\$1,415,592
	<b>Sub total</b>	<b>\$1,586,667,277</b>	<b>\$1,715,919,755</b>
<b>Other</b>			
	Premium Free Dispensing Incentive <sup>2</sup>	\$157,944,399	\$0
	Electronic Prescription Fee	\$13,455,626	\$14,877,612
	<b>Sub total</b>	<b>\$171,400,025</b>	<b>\$14,877,612</b>
	<b>Total<sup>3</sup></b>	<b>\$10,121,017,146</b>	<b>\$10,644,532,438</b>

**Summary of Medicines, Wholesalers, and Pharmacy Costs**

Medicines cost	\$6,962,682,865	\$7,362,814,544
Wholesale cost	\$409,523,060	\$425,185,142
Pharmacy cost	\$2,748,811,221	\$2,856,532,752
<b>Total</b>	<b>\$10,121,017,146</b>	<b>\$10,644,532,438</b>

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

\* Includes Efficient Funding of Chemotherapy (EFC) items dispensed by community pharmacies and friendly societies from March 2021 (EFC excluded prior to this as the pricing components were not available in the PBS online claims data).

\* Includes private and public hospital HSD claims dispensed by community pharmacies and friendly societies.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. The Premium-free Dispensing Incentive (PFDI) was discontinued from 1 July 2020, with funding reallocated to other dispensing remuneration under the 7th Community Pharmacy Agreement.

3. Health's 2020-21 Annual Report lists the administered expenses for pharmaceutical benefits as \$13.8 billion. The difference between that figure and the total figure above is attributable to:

- \* the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).
- \* the annual report data is based on accrual figures, whilst the above data is cash basis;
- \* the annual report does not include patient contributions;
- \* the annual report data does not include the Premium Free Dispensing Incentive (PFDI) or EPF;
- \* the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and
- \* the annual report also excludes the items in the footnote 1 above.

**Table 18: CPA Professional Pharmacy Programs Expenditure, 2020-21**

Under the Seventh CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under the 7CPA in 2020-21 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$18,100,000
Rural Pharmacy Workforce Program	\$4,875,000
Medication Management services	\$83,052,497
Medication Adherence services	\$110,594,420
Aboriginal & Torres Strait Islander programs	\$4,969,958
Pharmacy Program administration fees	\$8,271,755
<b>Programs Total</b>	<b>\$229,863,630</b>

**Notes:**

1. For the Programs administration arrangements for 2020-21, the total funding provided to the Pharmacy Programs Administrator (i.e. Australian Healthcare Associates) was \$229,423,715 (accrual figure). Of this, \$8,271,755 was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Programs Administrator administration fees was 3.60% of the total funds.

2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.

3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,000
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$300,000
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$800,000
RPLO	\$840,000
<b>Program Total</b>	<b>\$4,875,000</b>

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$41,700,000
Residential Medication Management Review (RMMR)	\$20,352,497
Home Medicines Review (HMR)	\$21,000,000
<b>Program Total</b>	<b>\$83,052,497</b>

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids (Pharmacy Practice Incentives)	\$101,194,420
Staged Supply (Pharmacy Practice Incentives)	\$9,400,000
<b>Program Total</b>	<b>\$110,594,420</b>

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Supporting \$100 Pharmacy Support Allowance	\$2,100,000
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,529,958
<b>Program Total</b>	<b>\$4,969,958</b>

**Table 19: Actual Costs of Major Components of CPA\*, 2020-21**

Component	Expenditure
Pharmacy remuneration	\$2,856,532,752
Wholesale remuneration	\$425,185,142
Professional programs	\$229,863,630
Community Services Obligation (CSO)	\$222,553,000
<b>Total</b>	<b>\$3,734,134,524</b>

\* The current Community Pharmacy Agreement is the 7<sup>th</sup> CPA.

**Notes:**

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from the Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

**Table 20: Community Services Obligation (CSO) Expenditure, 2020-21**

Component	Expenditure
CSO funding pool	\$221,264,342
CSO admin	\$1,288,658
<b>Total</b>	<b>\$222,553,000</b>

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

## PBS INFORMATION LINE REPORT, 2020-2021

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2020 – 30th June 2021, the information line answered 6,105 calls. This was a decrease of 2.6% from the previous financial year, where 6,271 calls were answered.

### Breakdown of calls by month:

Month	Number of calls
July 2020	715
August 2020	626
September 2020	574
October 2020	508
November 2020	454
December 2020	356
January 2021	492
February 2021	530
March 2021	456
April 2021	415
May 2021	451
June 2021	528
<b>Total</b>	<b>6,105</b>

## National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2021 until 30 June 2024.

The NDSS is managed by the Department of Health through the Diabetes Products Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumables products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,500 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%
2020-21	443,572	1.19%	945,903	1.88%	1,389,475	1.65%

### National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2020-21 financial year was \$186m. From 2016-17, NDSS Registrant co-payments are now returned to Consolidated Revenue.

PBS Expenditure and Prescriptions 2020-21

**Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2020-21)**

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes

-Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure  
 -For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category  
 -Exclude under co-payment prescriptions

Safety Net

Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2020-21

**Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2020-21) Continued**

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456
2017-18	13,332,423	2,616,813	15,949,236	148,018,925	37,047,645	185,066,570	201,015,806	398,051	2,645,790	204,059,647
2018-19	13,490,749	2,637,491	16,128,240	148,244,490	37,499,894	185,744,384	201,872,624	402,827	2,813,028	205,088,479
2019-20	13,873,735	2,577,950	16,451,685	148,326,789	40,280,313	188,607,102	205,058,787	418,823	2,992,062	208,469,672
2020-21	13,964,979	2,786,869	16,751,848	142,609,817	50,554,872	193,164,689	209,916,537	360,378	3,243,844	213,520,759

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programs.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by the Services Australia.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2020-21)

GOVERNMENT EXPENDITURE	GEN	CONC	PENS	SAFETY NET	SUB TOTAL	HOSP & MISC	TOTAL GOVT COST	PATIENT CONTRIBUTION	GEN	CON	TOTAL	TOTAL COST PRESCRIPTIONS	TOTAL with S.100 & Misc
1948/49	132,536				132,536	165,538	298,074				-	132,536	298,074
1949/50	346,682				346,682	262,696	609,378				-	346,682	609,378
1950/51	5,453,558				5,453,558	406,768	5,860,326				-	5,453,558	5,860,326
1951/52	13,424,294		715,264		14,139,558	1,230,536	15,370,094				-	14,139,558	15,370,094
1952/53	12,399,568		1,457,316		13,856,884	573,734	14,430,618				-	13,856,884	14,430,618
1953/54	14,320,372		2,021,560		16,341,932	2,116,894	18,458,826				-	16,341,932	18,458,826
1954/55	16,303,940		2,589,672		18,893,612	2,585,322	21,478,934				-	18,893,612	21,478,934
1955/56	18,061,092		3,015,920		21,077,012	2,697,858	23,774,870				-	21,077,012	23,774,870
1956/57	17,171,670		3,586,200		20,757,870	2,675,776	23,433,646				-	20,757,870	23,433,646
1957/58	22,826,484		4,246,490		27,072,974	2,995,004	30,067,978				-	27,072,974	30,067,978
1958/59	33,112,570		5,034,746		38,147,316	3,798,278	41,945,594				-	38,147,316	41,945,594
1959/60	36,714,806		7,148,446		43,863,252	4,808,090	48,671,342	1,890,756			1,890,756	45,754,008	50,562,098
1960/61	34,282,496		14,676,698		48,959,194	6,803,248	55,762,442	10,324,740			10,324,740	59,283,934	66,087,182
1961/62	44,632,488		18,194,996		62,827,484	7,552,282	70,379,766	13,007,776			13,007,776	75,835,260	83,387,542
1962/63	47,093,026		19,830,750		66,923,776	9,986,382	76,910,158	14,742,448			14,742,448	81,666,224	91,652,606
1963/64	46,460,998		20,601,714		67,062,712	11,775,958	78,838,670	15,573,804			15,573,804	82,636,516	94,412,474
1964/65	48,929,748		21,564,420		70,494,168	11,708,442	82,202,610	16,841,354			16,841,354	87,335,522	99,043,964
1965/66	53,078,046		24,071,127		77,149,173	14,634,501	91,783,674	17,481,228			17,481,228	94,630,401	109,264,902
1966/67	56,655,939		29,280,268		85,936,207	15,344,592	101,280,799	18,347,036			18,347,036	104,283,243	119,627,835
1967/68	56,800,249		32,115,335		88,915,584	16,218,859	105,134,443	18,504,345			18,504,345	107,419,929	123,638,788
1968/69	64,024,983		36,609,257		100,634,240	17,739,118	118,373,358	20,129,402			20,129,402	120,763,642	138,502,760
1969/70	73,227,887		41,068,702		114,296,589	22,421,727	136,718,316	21,941,691			21,941,691	136,238,280	158,660,007
1970/71	88,176,385		45,180,856		133,357,241	26,917,666	160,274,907	24,384,028			24,384,028	157,741,269	184,658,935
1971/72	90,061,869		52,005,350		142,067,219	31,201,229	173,268,448	35,466,642			35,466,642	177,533,861	208,735,090
1972/73	87,431,438		58,139,459		145,570,897	32,061,691	177,632,588	48,640,243			48,640,243	194,211,140	226,272,831
1973/74	108,066,351		66,802,821		174,869,172	43,426,672	218,295,844	59,015,335			59,015,335	233,884,507	277,311,179
1974/75	131,341,320		80,586,986		211,928,306	50,368,781	262,297,087	66,827,982			66,827,982	278,756,288	329,125,069
1975/76	149,033,245		107,317,318		256,350,563	27,490,706	283,841,269	95,244,660			95,244,660	351,595,223	379,085,929
1976/77	111,077,507		115,201,775		226,279,282	8,623,582	234,902,864	111,676,421			111,676,421	337,955,703	346,579,285
1977/78	118,303,375		127,911,837		246,215,212	9,832,410	256,047,622	115,025,169			115,025,169	361,240,381	371,072,791
1978/79	110,425,438		151,125,681		261,551,119	9,767,502	271,318,621	129,540,759			129,540,759	391,091,878	400,859,380
1979/80	101,185,503		166,361,113		267,546,616	7,088,452	274,635,068	123,418,168			123,418,168	390,964,784	398,053,236
1980/81	107,903,558		191,043,798		298,947,356	10,267,063	309,214,419	129,923,272			129,923,272	428,870,628	439,137,691
1981/82	139,547,856		239,894,493		379,442,349	11,377,241	390,819,590	157,957,635			157,957,635	537,399,984	548,777,225
1982/83	131,773,044	11,100,973	272,707,495		415,581,512	14,685,428	430,266,940	170,617,530	5,882,844		176,500,374	592,081,886	606,767,314
1983/84	114,638,367	39,276,732	317,819,660		471,734,759	17,490,165	489,224,924	166,043,447	19,975,026		186,018,473	657,753,232	675,243,397
1984/85	142,439,672	43,266,712	356,213,948		541,920,332	17,877,162	559,797,494	201,142,242	20,208,116		221,350,358	763,270,690	781,147,852
1985/86	138,365,148	50,172,930	408,026,507		596,564,585	19,258,116	615,822,701	222,286,396	20,715,057		243,001,453	839,566,038	858,824,154
1986/87	140,571,611	59,738,152	514,236,037		714,545,800	23,457,302	738,003,102	167,130,307	22,048,299		189,178,606	903,724,406	927,181,708
1987/88	111,740,361	51,574,897	747,536,316	159,418,168	910,851,574	35,612,019	946,463,593	117,938,301	18,839,286		136,777,587	1,047,629,161	1,083,241,180
1988/89	132,040,607	63,272,252	795,027,196	138,531,290	990,340,055	33,194,842	1,023,534,897	147,704,171	20,603,194		168,307,365	1,158,647,420	1,191,842,262
1989/90	170,039,203	74,757,555	890,753,297	150,064,548	1,135,550,055	43,852,385	1,179,402,440	162,587,554	22,174,539		184,762,093	1,320,312,148	1,364,164,533
1990/91	157,783,001	342,720,328	428,743,821	580,709,870	1,094,463,443	64,798,247	1,159,261,690	132,120,868	91,672,986		223,793,854	1,318,257,297	1,383,055,544

**Note**

- Free Pensioner category removed from 1 Nov 90, \$2.50 copayment and free safety net introduced for all Concessionals
- Dr's Bag prior to 90/91 included in General
- from 90/91 (\$12,255,895) included in Misc

**Safety Net**

- For Gen & Conc prior to 90/91 is included in Pensioner
- For 90/91 S/net includes both pre & post 1/11/90 free Snet
- Gen S/net 1 included in Concess in 90/91
- Gen S/net 2 (free) 1 Jan 91 to 31 Dec 93

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2020-21) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
1991/92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355	
1992/93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766	
1993/94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688	
1994/95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803	
1995/96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162	
1996/97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134	
1997/98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690	
1998/99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100	
1999/00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569	
2000/01	662,099,200	128,173,886		790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873	
2001/02	691,204,687	148,498,520		839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991/92	128,988,053	6,043,066		135,031,119	173,201,117		173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578		173,170,347	186,726,902		186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025		194,086,500	201,596,301		201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816		230,302,567	214,241,512		214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699		251,518,516	226,583,554		226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980		278,091,046	252,104,590		252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016		294,364,268	276,440,026		276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417		318,219,469	283,117,963		283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337		345,587,886	306,183,001		306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837		406,786,373	337,379,028		337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336		443,838,957	362,237,529		362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
<b>DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)</b>											
1990/91	12,255,895										
1991/92	14,514,725										
1992/93	16,082,655										
1993/94	16,679,933										
1994/95	15,674,643										
1995/96	16,202,098										
1996/97	15,769,173										
1997/98	14,953,823										
1998/99	13,370,491										
1999/00	10,754,395										
2000/01	10,343,534										
2001/02	9,803,682										

note- from 91/92 all figures are sourced from the Services Australia processing where available  
 -miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2020-21) Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOV'T EXP	
2002/03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188	
2003/04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000	
2004/05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157	
2005/06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784	
2006/07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330	
2007/08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974	
2008/09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540	
2009/10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155	
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803	
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119	
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924	
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2002/03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003/04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004/05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005/06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006/07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007/08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008/09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009/10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2002/03	\$9,510,606									
2003/04	\$9,408,669									
2004/05	\$9,365,803									
2005/06	\$10,063,803									
2006/07	\$10,698,205									
2007/08	\$13,468,779									
2008/09	\$14,533,302									
2009/10	\$13,571,776									
2010-11	\$14,228,520									
2011-12	\$12,974,506									
2012-13	\$14,755,085									
note- from 91/92 all figures are sourced from the Services Australia processing where available										
-miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments										

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP &amp; MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Pharmaceutical Benefits Scheme History - Government Expenditure &amp; Patient Contribution, 1948-49 to 2020-21 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
2017-18	\$1,981,594,072	\$101,429,150	\$2,083,023,223	\$5,127,198,161	\$1,236,961,876	\$6,364,160,037	\$8,447,183,260	\$16,568,617	\$3,139,112,049	\$11,602,863,926
2018-19	\$2,005,253,340	\$102,355,665	\$2,107,609,004	\$4,844,366,564	\$1,243,669,704	\$6,088,036,267	\$8,195,645,272	\$16,002,440	\$3,487,069,944	\$11,698,717,656
2019-20	\$2,142,135,695	\$104,447,648	\$2,246,583,343	\$4,918,980,015	\$1,370,238,848	\$6,289,218,863	\$8,535,802,207	\$16,858,042	\$3,954,440,736	\$12,507,100,984
2020-21	\$2,247,872,026	\$119,454,635	\$2,367,326,661	\$4,966,331,531	\$1,787,418,829	\$6,753,750,360	\$9,121,077,021	\$14,968,393	\$4,436,944,506	\$13,572,989,921
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	TOTAL EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	\$880,418,081	-	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
2017-18	\$484,120,874	\$16,143,997	\$500,264,871	\$915,055,636	-	\$915,055,636	\$1,415,320,507	\$9,862,503,767	\$40,183,135	\$13,058,367,568
2018-19	\$494,513,005	\$16,477,196	\$510,990,200	\$929,032,414	-	\$929,032,414	\$1,440,022,615	\$9,635,667,887	\$44,642,304	\$13,183,382,575
2019-20	\$521,326,935	\$17,796,260	\$539,123,195	\$910,922,527	-	\$942,085,948	\$1,450,045,722	\$9,985,847,929	\$53,947,851	\$14,011,094,558
2020-21	\$521,326,935	\$17,796,260	\$539,123,195	\$910,922,527	-	\$910,922,527	\$1,450,045,722	\$10,571,122,743	\$53,947,851	\$15,076,983,494
TOTAL COST *	Total cost for Section 85 (Patient payment + Government benefit)									
TOTAL EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + Government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									
2017-18	\$16,568,617									
2018-19	\$16,002,440									
2019-20	\$16,858,042									
2020-21	\$14,968,393									

**Notes:**

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by the Services Australia.

From 1991-92 all figures are sourced from the Services Australia processing where available

Miscellaneous and section 100 expenditure sourced from Department of Health and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Section 100 programs, other ungrouped expenditure

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.